

# Index

---

Notes

As the subject of this book is rehabilitation, entries have been kept to a minimum under this heading. Users are advised to seek more specific entries.

Abbreviations

ADHD – attention deficit hyperactivity disorder  
CIMT – constraint-induced movement therapy  
fMRI – functional magnetic resonance imaging  
MRI – magnetic resonance imaging  
TBI – traumatic brain injury

A-B-A assessment design, 328, 329  
A-B assessment design, 327–328, 329  
ability over-estimation, self-efficacy, 237  
abnormal development, behavioral self-regulation in children, 494  
Aβ protein *see* beta-amyloid protein (Aβ)  
abulia, 213  
Academy of Neurologic Communication Disorders and Sciences (ANCDS)  
    aphasia therapy, 436  
    cognitive rehabilitation reviews, 108  
acceleration-deceleration forces, TBI, 507  
accommodation  
    compensation, 26  
    organic cognitive impairment, 29  
N-acetylaspartate (NAA), magnetic resonance spectroscopy, 133  
acetylcholine  
    in injury, 308  
    Parkinson’s disease, 337  
    TBI, 322  
acetylcholinesterase, Alzheimer’s disease, 335

- acetylcholinesterase inhibitors, clinical trials
  - Alzheimer's disease, 339–341
  - dementia with Lewy bodies, 342
- acquired focal brain damage, intra-individual variability, 48
- activation
  - compensation, 28
  - neurological recovery, 168
  - injury pattern differences, 164
- activities of daily living (ADLs)
  - activity assessment, 94
  - dementia intervention studies, 338, 339
  - exercise, negative findings, 259
- adaptation, compensation, 27
- adaptive behaviors, self-efficacy, 237
- “adaptive plasticity”, neurogenesis, 352
- addiction, plasticity, 17
- adrenalectomy, 65
- adrenal steroids, 63–66
  - see also* catecholaminergic system
- adrenergic receptor 1 agonists
  - alpha-2-adrenergic mechanisms, 301
  - working memory, 301
- aerobic activity, 259
  - see also* exercise/physical activity
- aerobic power, 258
- affective reversal learning, behavioral/emotional
  - self-regulatory function, 466
- age-related effects, 149
  - brain activity, increased, 152–154
  - brain activity, reduced, 150, 151
  - brain networks, 154–156, 157
  - cerebral microangiopathy, 371
  - community-based interventions, 241
  - coping, 236
  - estrogen, memory effects, 67
  - intra-individual variability, 47
  - locus of control, 236
  - memory, 149
  - neurogenesis, 357
  - neurotrophic factors, exercise/physical activity, 423
  - plasticity *see* neuronal networks
  - self-efficacy, 237
- aging, 124
  - functional imaging, 122
  - healthcare costs, 568
  - healthy, 417
  - MRI subcortical hyperintensities, 132
  - psychosocial factors, 233
- AIP *see* Awareness Intervention Program (AIP)
- akinetic mutism, 213
- Akt signal transduction *see* PI3K/Akt signal transduction
- alertness, TBI effects, 509
- allostasis, 62–78
- alpha-2-adrenergic receptors, 301
  - see also* noradrenergic function
- alpha-numeric labeling, proximal memory
  - aids, 524
- Alzheimer, Aloysius, 128
- Alzheimer's disease, 125
  - Blessed Dementia Scale, 335
  - brain networks, 156
  - cerebral amyloid angiopathy association, 365, 371
  - cerebral hypoperfusion, 262
  - compensation, 30
  - definition, 251
  - diet
    - docosahexaenoic acid, 278
    - excess fat, 277
    - high-fat diets, 277
    - omega-3 fatty acids, 278
  - executive functions, 250, 264
  - exercise, 250, 419
    - intervention studies *see below*
    - negative findings, 259
    - neurotrophic factors, 423
  - gait disorders, 265
  - generation of material-to-be-remembered, 547
  - genetics, 335
  - insulin signaling, 273, 274, 275
  - intra-individual variability, 48
  - memory, 541, 542, 543
  - “mild cognitive impairment”, 335
  - nitric oxide metabolism, 261
  - pathology, 334–335
  - pharmacological therapy, 296, 312, 322, 339–342
    - see also specific drugs*
  - prevalence, 124, 334
  - vascular disease, 260
- Alzheimer's disease, exercise intervention studies, 252–256
- Alzheimer's Disease Assessment Scale (ADAS-cog), 338, 339, 340
- amantadine
  - attention rehabilitation, 510
  - energization function rehabilitation, 474
- American Academy of Neurology, 109
- 21-aminosteroids, 305

- amitriptyline, 211
- AMPA receptor(s), 303
- AMPA receptor blockers, 304
- amphetamines, 308
  - plasticity in rehabilitation, 15
- amplitude, mismatch negativity, 190
- amygdala, chronic stress effects, 65
- amyloid angiopathy, MRI, 130, 144
- anatomic principles, energization functions, 465
- androgens, 66, 68
- angiitis, cerebral amyloid angiopathy, 365
- angiogenesis
  - exercise/physical activity, 418, 420–421
  - functional imaging, 164
- angiopoietin, exercise/physical activity, 420
- anhedonia, depression, 208
- animal models/studies, 387
  - cognitive neurorehabilitation, 567
  - complex environments, 9
  - exercise/physical activity *see* exercise/physical activity
  - focal brain lesion localization, 135
  - neural stem cell therapy, 376
  - nitric oxide, 262
  - plasticity
    - lesion studies, 12, 13
    - mPFC lesions, 14
  - stroke, neural stem cell therapy, 385
  - ventral hippocampal lesions, plasticity, 17
- anisotropic diffusion, diffusion tensor imaging, 134
- anomia, semantic memory, 533
- anosognosia, 218–231
- anosognosia, treatment, 219–220, 222–223
  - considerations, 225–226
  - cost-effectiveness studies, 228
  - long-term follow-up studies, 228
  - outcome measures, 220–222, 226–228
- anterior cerebral artery aneurysms, 468, 469
- anterior cingulate cortex *see* frontal subcortical circuits; motivation
- anterior communicating artery (ACoA), stroke, 468, 470
- anterior system for selection and control of responses, attention, 508
- anterograde memory, TBI, 321
- anticholinesterase (AChE) inhibitors, 296
- anticonvulsants, TBI, 323
- antidepressants
  - leptin effects, 69
  - neurogenesis, 356
- antioxidants, 305
  - clinical trials, 340
- antipsychotics, TBI, 324
- antisocial behavior, 494
- anxiety disorders, 205, 211–212
  - compensation, 24
  - corticosteroids, 65–66
- apathy, 206, 212–213
  - Alzheimer’s disease, 264
  - assessment/treatment, 213
- apathy evaluation scale (AES), 474
- aphasia, 435–448
  - anosognosia, 219
  - aphasia, recovery, 169–172
  - aphasia therapy, 399, 437
    - clinical trials, 436
    - functional impact, 442–444
  - see also* language production therapy; *specific therapies*
- apolipoprotein E gene, Alzheimer’s disease, 335
- apomorphine, neglect syndrome rehabilitation, 459
- apoptosis
  - intracellular calcium ions, 304
  - secondary neurological diseases/disorders, 303
- applicability, phase III clinical trial, 86
- APP* mutation, 366, 367
- areal dependency, plasticity *see* plasticity
- Arm Motor Ability Test (AMAT), 406
- arousal, anosognosia treatment, 226
- arousal, sustained attention and vigilance system, attention, 508
- arteriosclerotic microangiopathy, ischemic vascular disease, 363
- aspartate, neurotoxicity, 303
- assessment(s)
  - anosognosia neurorehabilitation, 219
  - TBI pharmacological therapy, 327–328
- Assessment of Motor and Process Skills (AMPS), 95
- assimilation, compensation, 26
- astrocytes, ischemic vascular disease, 362
- atheroemboli, ischemic vascular disease, 363
- atherosclerosis
  - functional imaging, 164
  - nitric oxide, 261
- atrophy, Alzheimer’s disease, 335
- attention, 299–300
  - anterior system for selection and control of responses, 508
  - arousal, sustained attention and vigilance system, 508
  - assessment, 98

- attention (cont.)  
 definition, 508  
 focusing, Brief Mindfulness Training, 511  
 MRI subcortical hyperintensities, 132  
 neural substrate, 298  
 pharmacological therapy, 311–312, 313  
*see also* attention, rehabilitation post-TBI  
 rehabilitation post-TBI *see below*  
 resource allocation, 299  
 sensory selective attentional system, 508  
 TBI, 321, 508–510  
   rehabilitation *see below*  
 tests  
   Alzheimer's disease exercise training, 252  
   Digit Span test, 508  
   Digit Symbol Coding test, 508  
   divided attention tasks, 509  
   selective attention tasks, 509  
   Sustain Attention and Response task, 508  
   Sustained Attention to Response Task, 509, 510  
   Symbol Digit Modalities test, 508  
   Trail Making Test, 508  
 attention, rehabilitation post-TBI, 507–521  
 attentional control process, dispersion, 50  
 attention deficit hyperactivity disorder (ADHD), 311, 322, 399, 487–499  
 attention-demanding actions, neurological recovery, 166  
 Attention Questionnaire, 98  
 Attention Rating and Monitoring Scale (ARMS), 98  
 atypical antipsychotics, TBI, 324  
 auditory comprehension treatments *see* language comprehension  
 auditory cortex, translational research, 84  
 auditory cueing, 474  
 auditory discrimination learning  
   neuroelectric recordings, 182  
   neuromagnetic recordings, 182  
 auditory evoked fields (AEFs), 186  
 auditory evoked potentials (AEPs), 186  
 auditory evoked responses, somatosensory evoked responses vs., 192  
 auditory learning  
   mismatch negativity, 185–190  
   neural activity measurement, 186–191  
 auditory tests, attention rehabilitation, 510–512  
 autobiographical memory, 149  
 AutoCITE, 408  
 automation, CIMT, 408  
 autopsy studies, ischemic vascular disease, 360  
 aversive consequences, CIMT, 402  
 avoidance conditioning  
   neuroelectric recordings, 182  
   neuromagnetic recordings, 182  
 avoidance-oriented coping, 235  
 awareness, compensation *see* compensation  
 Awareness Intervention Program (AIP)  
   deficit awareness, 475  
   post-TBI anosognosia therapy studies, 224  
 Awareness Questionnaire, 222  
 awareness training, anosognosia, 220  
 Baking Tray Task, 98  
 Barthel Index  
   activity assessment, 94  
   stroke, 94  
 basal forebrain, vascular dementia, 260  
 basal ganglia  
   apathy, 213  
   cerebral hypoperfusion, 263  
   executive functioning, 488  
   gait, 263  
 baseline measurements, TBI pharmacologic therapy, 327  
 BAY x 3702, in injury/repair, 309  
 BDNF *see* brain-derived neurotrophic factor (BDNF)  
 beamformer techniques, neuroelectric recordings, 185  
 Beck Depression Inventory II, 96  
 behavioral animal studies, exercise/physical activity *see* exercise/physical activity  
 Behavioral Assessment of the Dysexecutive syndrome (BADS)  
   cognitive activity, 97  
   executive functions, 99  
 behavioral contract (BC), CIMT, 411  
 behavioral disorders  
   cerebral microangiopathy, 370  
   cognitive activity assessment, 96  
   cognitive neurorehabilitation vs., 573  
   spatial neglect, 172  
   variability, 5  
 behavioral/emotional functions *see* frontal lobe functions  
 Behavioral Inattention Test (BIT)  
   cognitive activity, 97  
   visual neglect, 98  
 Behavioral Regulation Index, 495  
 behavioral score, neurological recovery vs., 164  
 behavioral self-regulation, in children, 493–495

- behavioral therapies
  - energization function rehabilitation, 475
  - intra-individual variability, 53
  - neglect syndrome *see* neglect syndrome rehabilitation
- TBI, 399
- Behavior Rating Inventory of Executive Function (BRIEF)
  - in children, post-TBI, 495
  - everyday activities, 495
  - TBI vs. ADHD, 496
- benzodiazepines, TBI, 324
- beta-amyloid protein (A $\beta$ )
  - Alzheimer's disease, 334
  - cerebral amyloid angiopathy, 364
  - familial cerebral amyloid angiopathy, 367
  - insulin signaling, 275
- bias
  - eligibility criteria, 111
  - research evaluation, 106
- BICRO39 (Brain Injury Community Rehabilitation Outcome 39), 39, 95
- BI-ISG (Brain Injury-Interdisciplinary Special Interest Group), 107
- Binswanger's disease, MRI subcortical hyperintensities, 127, 128
- Binswanger's subcortical leukoencephalopathy (BSLE), 364, 365
- biofeedback, ADHD, 499
- bipolar affective disorder, 210–211
- blinding
  - methodological quality evaluation *see* methodological quality evaluation
  - single subject experimental methods *see* single subject experimental methods
- blood supply, lesion-behavior analysis, 141
- blood vessel aging, functional imaging, 164
- blunt trauma, TBI, 507
- body deficits, 91
- body functions, 91
- body structure
  - definition, 87
  - outcome measures, 87
- BOLD response, functional imaging, 164, 165
- bone morphogenic proteins, neurogenesis, 306
- Bonferroni correction, lesion-behavior analysis, 141
- “bottom-up” system, attention, 299
- boundary conditions
  - neuroelectric recordings, 195
  - neuromagnetic recordings, 195
- BR12 mutations, 368
- brain
  - alpha-2-adrenergic receptors, 301
  - compensation changes *see* compensation
  - damage/injury
    - activity measurement, 164
    - aging-related changes vs., 152, 156
    - awareness/self-regulation, 27
    - compensation, 32
    - plasticity *see* plasticity
    - see also* traumatic brain injury (TBI)
  - function understanding, 571
  - imaging techniques, memory impairment
    - rehabilitation *see* memory rehabilitation, post-injury
  - networks, aging-related changes *see* age-related effects
  - regions, adult neurogenesis, 350
  - weight, plasticity models, 9
- Brain Age, 417
- brain-derived neurotrophic factor (BDNF), 277, 307
  - compensation, 30
  - corticosterone effects, 65
  - enriched housing effects, 382
  - exercise/physical activity, 422
  - neural stem cell therapy, 383
  - neurogenesis, 306, 382, 383
- Brain Injury Community Rehabilitation Outcome 39 (BICRO39), 95
- Brain Injury-Interdisciplinary Special Interest Group (BI-ISG), 107
- Brief Mindfulness Training *see* attention, rehabilitation post-TBI
- Broca's area, aphasia recovery, 171
- Brodmann areas
  - focal brain lesion localization, 136
  - lesion-behavior analysis, 140
- bromocriptine
  - attention rehabilitation, 510, 512
  - energization function rehabilitation, 474
  - neglect syndrome rehabilitation, 459
  - in recovery, 308
  - TBI, 324
- bromodeoxyuridine assays, adult neurogenesis, 348

- Bronx Aging Study, 549
- buffer/substitution, compensation, 28
- Buschke–Fuld Selective Reminding Test, 338
- CA1 pyramidal neurons, 67
  - androgens, 68
  - in injury/repair, 310
- CA3, chronic stress effects, 64
- CA3 cells, loss, 310
- CAA *see* cerebral amyloid angiopathy (CAA)
- CADASIL *see* cerebral autosomal dominant arteriography with subcortical infarcts and leukoencephalopathy (CADASIL)
- caffeine, 550
- calcium channel blockers, 305
- calcium ions, intracellular, 304, 309
- calpains
  - in cell death, 305
  - intracellular calcium ions, 304
- Cambridge Cognitive Examination (CAMCOG), 262
- cancellation tasks, neglect syndrome, 450
- carbamazepine
  - bipolar affective disorder, 211
  - TBI, 324
- carbohydrate metabolism, 69
- cardiovascular disease (CVD), 273
- caregiver contract (CC), CIMT, 412
- CART *see* codeine and amphetamine regulated transcript (CART)
- case-control studies, comprehensive day treatment programs, 240
- case study, variability, 52–53
- caspases
  - in cell death, 305
  - intracellular calcium ions, 304, 305
- catecholaminergic system, 307–308
  - antagonists, 308
  - augmentation, 308, 313, 314
  - working memory, 299
- categorization, proximal memory aids, 524
- Catherine Bergego Scale, 98
- “cautious gait”, Alzheimer’s disease, 265
- cell damage/death
  - calpains, 305
  - caspases, 305
  - intracellular calcium ions, 304
- cellular processes
  - neurogenesis, 352
  - plasticity in brain injury, 12
- central (cortico-limbic) blindness, anosognosia, 219
- central cholinergic tone, injury/repair, 308–309
- central GABA tone
  - effects, 309
  - injury/repair, 309
- central nervous system (CNS), inflammation, 276
- central neurotransmitter tone modulation, repair/recovery enhancement, 307–310
- central serotonin, in injury/repair, 309–310
- cerebellum, intra-individual variability, 49
- cerebral amyloid angiopathy (CAA), 362, 364–366, 367, 369
  - Alzheimer’s disease, 260, 365, 371
  - familial *see* familial cerebral amyloid angiopathy (fCAA)
  - see also* ischemic vascular disease (IVD)
- cerebral autoregulation, nitric oxide, 261
- cerebral autosomal dominant arteriography with subcortical infarcts and leukoencephalopathy (CADASIL), 362, 369
  - definition, 368–369
- cerebral blood flow, exercise *see* cerebral hypoperfusion; exercise/physical activity
- cerebral functions, localization, 6–7
- cerebral hypoperfusion
  - Alzheimer’s disease *see* Alzheimer’s disease
  - cognition, 262–263
  - executive dysfunction, 263–264
  - frontotemporal dementia, 263, 265
  - gait, 263–264
  - nitric oxide, 261–262
  - vascular dementia *see* vascular dementia (VaD)
  - vascular disease, 260–261
  - white matter lesions, 263–264
- cerebral microangiopathy, 369–372
- cerebral small vessel disease, 360–375
  - dementia, 126
  - see also* ischemic vascular disease (IVD)
- cerebrolysin, 305
- cerebrovascular accidents
  - anosognosia, 219, 220, 222
  - see also* stroke
- cerebrovascular disease (CVD), 125
  - Alzheimer’s disease comorbidity *see* Alzheimer’s disease
  - diet/nutrition, 273
  - ischemic vascular disease, 360
  - MRI subcortical hyperintensities, 132
  - see also* stroke

- Charcot–Bouchard aneurysms, 363, 364
  - chemotaxy, neurogenesis, 353
  - $\chi^2$  analysis, 141
  - choline acetyltransferase (ChAT)
    - Alzheimer’s disease, 335
    - dementia with Lewy bodies, 337
  - cholinergic antagonists, 308
  - cholinergic system
    - Alzheimer’s disease, 335
    - exercise and nitric oxide, 262
    - working memory, 299
  - cholinesterase inhibitors
    - age-related memory rehabilitation, 550
    - attention, 312
    - clinical trials, 343
    - vascular dementia, 343
  - Chonhqing Aging Study, 549
  - chronic stress *see* stress
  - citalopram, depression, 210
  - clasmotodendrosis, MRI, 131, 144
  - classical conditioning, 182
  - Classification and Regression Tree method (CART), 42
  - CLASS study, 309
  - Clinical Dementia Rating scale (CDR), 338
  - clinical trials, 80–81
    - cognitive neurorehabilitation, 572
    - phase I, 4, 6–21
    - phase II, 4, 6–8
    - phase III, 4, 6
    - psychosocial factors, 245
    - see also* randomised clinical trials (RCTs)
  - Clinician’s Global Impression of Change (CGIC), 338
  - Clinician’s Interview Based Impression of Change with caregiver input (CIBIC-plus)
    - dementia intervention studies, 338, 339
    - memantine clinical trials, 341
  - clock-drawing tasks, ADHD, 492
  - clomethiazole, 309
  - clozapine, bipolar affective disorder, 211
  - Cochrane reviews
    - aphasia therapy, 436
    - community-based interventions, 241
    - reviews (of cognitive rehabilitation), 108
  - codeine and amphetamine regulated transcript (CART)
    - dentate gyrus, 69
    - plasticity, 68
    - stress responses, 63
  - coefficient of variation, 44
  - cognitive activity assessment, 94, 96–100
  - cognitive–behavioral therapy (CBT)
    - attention rehabilitation, 515
    - compensation, 32
    - depression, 210
    - memory impairment rehabilitation, 534, 536
    - post-TBI anosognosia therapy studies, 224
    - psychosocial factors, 243
  - Cognitive Failures Questionnaire (CHQ), 99
  - cognitive function
    - aging-related changes, 154
      - compensation, 24
    - assessment *see above*
    - cerebral hypoperfusion, 262–263
    - control, executive functioning vs., 487
    - corticosteroid effects, 64–65
    - decline
      - compensation, 25
      - MRI subcortical hyperintensities, 132
    - defects *see below*
    - dietary antioxidants, 280
    - enriched housing, 381
    - neurogenesis *see* neurogenesis
    - optimism vs., 238, 239
    - performance vs., 573
    - self-efficacy vs., 238
    - variability, 50
  - cognitive function defects
    - apathy, 213
    - causes, 311
      - cerebrovascular disease, 125
      - insulin resistance, 276
      - metabolic syndrome, 276
      - neglect syndrome, 450
      - stroke, 377
      - TBI, 507
  - comorbidities, 311
  - as economic burden, 568
  - insulin, 69
    - signaling, 274
  - pharmacological therapy *see* pharmacological therapy
  - prevalence, 568
  - therapy *see* cognitive neurorehabilitation
- Cognitive Log (Cog-Log) scale, 99
- cognitive neurorehabilitation, 569
  - assessment, 566–568
  - attentional demands, 567
  - costs, 571
  - definition, 565

- cognitive neurorehabilitation (cont.)
  - efficacy, demonstrability, 570
  - everyday tasks, 570
  - evidence-based therapy, 570
  - examples, 570–573
  - future work, 565–574
  - investment in, 568
  - models, 570
  - multilevel integration, 566–567
  - protocol necessity, 570
  - psychosocial factors, 243
  - as science, 568–570
    - amelioration of symptoms, 572
    - brain function understanding, 571
    - clinical trials, 572
    - everyday life function, 572
    - imaging importance, 572
    - structure, planned, 571
    - testing, 572
- cognitive-phenomenological theories, psychosocial factors
  - theories/models, 233
- cognitive psychological models, post-TBI anosognosia
  - therapy studies, 223
- cognitive system recruitment, word level treatments, 438
- cognitive tests, outcome measures, 92
- collaterals, compensation, 29
- combination therapies
  - cognitive neurorehabilitation, 574
  - TBI, 323, 324
- commercial services, paging systems, 531
- communication difficulties, mood assessment, 96
- Communicative Activities of Daily Living, 99
- community-based autopsy studies, Alzheimer's disease-
  - cerebrovascular disease comorbidity, 126
- community-based interventions *see* psychosocial factors
- community-based investigations, ischemic vascular
  - disease, 360
- Community Integration Measure, 100
- compensation, 4, 22–38
  - aging-related changes, 154
- competitive spatial bias, neglect syndrome, 451
- complex environments, animal models *see* animal
  - models/studies
- complexity, treatment descriptions, 113
- compliance, treatment descriptions, 114
- comprehensive day treatment programs (CDTPs) *see*
  - psychosocial factors
- computational methods, MRI subcortical
  - hyperintensities, 132
- computerised lesion analysis, 137
- computerised tomography (CT)
  - introduction, 128
  - right hemisphere hypodensity, 137
- computerised training
  - attention rehabilitation, 510, 511
  - auditory comprehension treatments, 442
  - neglect syndrome rehabilitation, 455
  - selective attention rehabilitation, 512
- concentration, TBI, 322
- conditioned responses, CIMT, 403
- confrontation naming, word level treatments, 437
- connectivity, normal aging, 150
- constraint induced language therapy (CILT), 443
- constraint-induced movement therapy (CIMT), 397, 401,
  - 443, 570
  - adherence-enhancing behavioral methods, 410–412
  - application of, 405–407
    - stroke, 377
  - behavioral contract, 411
  - caregiver contract, 412
  - constraining use of more-impaired upper extremity, 410
    - protective safety mitt, 410
  - daily schedule, 412
  - definition, 401
  - efficacy, 401
  - historical aspects, 405
  - home diary, 411
  - home practice, 412
  - home skill assignment, 411–412
  - importance, 570
  - overcoming learned non-use, 402–404
  - protocols, 407–412
    - see-also individual protocols*
  - as rehabilitation model, 571
  - repetitive task-oriented training, 407–410
  - studies, 405
  - theoretical basis, 402–404
  - therapeutic factors, 412–413
  - use-dependent cortical reorganization, 404–405
  - without physical restraint, 410
- contextual therapy, psychosocial factors, 245
- continuous behavior, lesion-behavior analysis, 141
- continuous memory recovery, 42
- Continuous Performance Tasks, 512
- continuous scales, impairment measures, 93
- contralateral pattern, neurological recovery, 168
- Controlled Oral Word Association Test, 512
- coping *see* psychosocial factors



- coping skills group, 242
- copying objects, neglect syndrome, 450
- cortex
  - aging-related changes
  - functional imaging, 156
  - visual areas, 152
- neural stem cell therapy, 386
- plasticity, compensation, 29
- remodeling
  - event-related fields, 184
  - event-related potentials, 184
- cortical maps, 193
- corticobasal degeneration (CBD), 336
- corticosteroid(s)
  - anxiety effects, 65–66
  - chronic stress, 64
  - cognitive function effects, 64–65
  - dendritic retraction, 64
  - memory effects, 65–66
  - neural structure effects, 64–65
  - neurogenesis, 65
  - receptors, 64
- corticosteroid receptors, glial cells, 65
- corticosterone, 65
- corticostriatal dysfunction, ADHD, 497
- cortisol, neurological effects, 64
- cost-effectiveness
  - anosognosia neurorehabilitation, 228
  - cognitive neurorehabilitation, 571
- Craig Handicap Assessment and Reporting Technique, 100
- cross-sectional studies
  - exercise/physical activity *see* exercise/physical activity
  - neurological recovery, 169
- cued-recall tasks, compensation, 30
- Cueing Verbs Treatment (CVT), 439
- cues, word level treatments
  - creation, 437
  - hierarchies, 437
- current, apical dendrites, 184
- Cushing’s disease, 66
  - hippocampal atrophy, 64
  - steroid therapy, 70
- cystatin C mutations, 368
- cystic encephalomalacia, 362
- cystic infarcts, 362
- daily schedule (DS), CIMT, 412
- “Darwinian concept of stress”, 63
- data, scatter, 46
- data storage/analysis
  - neuroelectric recordings, 185
  - neuromagnetic recordings, 185
  - single subject experimental methods, 329
- “day-to-day” variability, 43
- decision making/motivation, children, 492–493
- declarative memory therapy, 313
- deep white subcortical hyperintensities, MRI, 129, 143
- deficit awareness *see* metacognitive function rehabilitation
- definition, three-dimensional MRI, 138
- delirium, pharmacological therapy, 302
- delivery and impact *see* Rothi’s revision of the Robey model
- dementia, 125–126
  - apathy, 213
  - exercise *see below*
  - pathology, 334–337
  - pharmacological therapy *see below*
  - see also specific diseases/disorders*
- dementia, exercise intervention studies, 256–258
- dementia, pharmacologic therapy, 296, 334–347
- dementia with Lewy bodies
  - compensation, 30
  - intra-individual variability, 48
  - Parkinsonism, 337
  - Parkinson’s disease, 337
  - pathology, 336–337
  - pharmacologic clinical trials, 342–343
- dendritic length, plasticity, 11
- dendritic morphology
  - age-related plasticity, 13
  - plasticity, 7
- dendritic retraction, corticosteroids, 64
- dendritic spines, estrogen receptors, 66
- denial of disability (DD), anosognosia treatment, 225
- density plots, lesion-behavior analysis, 141, 142
- dentate gyrus
  - androgens, 68
  - codeine and amphetamine regulated transcript, 69
  - neurogenesis, 65, 379
- Department of Veterans Affairs Taskforce on Aphasia, 436
- L-deprenyl, 308
- depression, 206–209
  - apathy *see* apathy
  - assessment, 208–210
  - cognition vs., 351
  - intra-individual variability, 49

- depression (cont.)  
   pseudodementia, 209–210  
   treatment, 210  
     memory impairment rehabilitation, 534, 536  
     pharmacotherapy, 207
- design features, distal memory aids, 525
- determinants  
   anosognosia therapy outcome, 219  
   psychosocial factors, 239
- device-requiring therapies *see* neglect syndrome rehabilitation
- DEX *see* Dysexecutive Questionnaire (DEX)
- dexamethasone suppression test, 209
- dextromethorphan, pseudobulbar affect treatment, 211
- DHA *see* docosahexaenoic acid (DHA)
- DHEA, 68
- DHT, 68
- diabetes mellitus, type-2 *see* type-2 diabetes mellitus
- diaschisis  
   functional imaging, 165  
   injury, 162  
   lesion-behavior analysis, 141
- diazepam, in stroke, 309
- dietary antioxidants, 272, 279–280
- diet/nutrition, 272–291  
   dietary restriction, 204  
     neurogenesis, 70  
   insulin resistance *see* insulin resistance (IR)  
   *see also specific nutrients*
- diffuse axonal injury (DAI), TBI, 303, 321, 469
- diffusion tensor imaging (DTI), 134  
   ADHD, 497  
   fractional anisotropy, 131, 134  
   MRI, 132  
   sensitivity, 133  
   structure, 133
- Digit Span test, 508
- Digit Symbol Coding test, 508
- Digit Symbol measures, 327
- direct cortical electrical stimulation, plasticity, 16
- directional motor defects, neglect syndrome, 451
- disability, outcome measures, 87
- disconnection syndrome, lesion-behavior analysis, 141
- discourse level training, verbal fluency, 440
- discovery phase, Rothi's revision of the Robey model, 82
- discrepancies, reviews (of cognitive rehabilitation), 108
- discriminating training, neural activity measurement, 188
- disengaging attention, neglect syndrome, 451
- dispersion  
   intra-individual variability, 43  
   variability *see* variability
- dispositional optimism, 238, 239
- distal memory aids *see* memory rehabilitation, post-injury
- distractability, TBI, 322
- distraction reduction, attention rehabilitation, 516
- distributed practice, memory impairment rehabilitation, 527
- diurnal rhythms, intra-individual variability, 47
- divided attention, 514  
   TBI effects, 509
- docosahexaenoic acid (DHA)  
   Alzheimer's disease, 278  
   in brain, 278  
   dietary supplementation effects, 279  
   gene expression effects, 279  
   PI3K/Akt signaling, 279
- domain-specific expertise, elderly memory rehabilitation, 553
- domain-specific functions, variability, 50
- donepezil  
   attention, 312  
   clinical trials  
     Alzheimer's disease, 339–340, 341  
     vascular dementia, 343  
   declarative memory, 313  
   executive functions, 313  
   memory, 313  
   TBI, 324
- dopamine, 300  
   TBI, 322
- dopamine agonists  
   apathy, 212, 213  
   in recovery, 308
- dopamine D1 receptor agonists  
   neglect syndrome rehabilitation, 459  
   spatial working memory, 300
- dopamine D1 receptor antagonists, 300
- dopamine D2 receptor agonists, 459
- dopaminergic drugs  
   apathy, 206  
   neglect syndrome rehabilitation, 459
- dopaminergic system, executive functions, 300
- dorsolateral prefrontal (DLPF) *see* frontal subcortical circuits
- dorsolateral stroke syndrome, 468
- double-blind trials, methodological quality evaluation, 112
- double dissociation of symptoms, neurological recovery, 175

- drive, definition, 204
- drugs
  - anxiety disorders, 212
  - development targets, Alzheimer’s disease, 335
  - induced behavioral sensitization, 8
  - induced morphological changes, 10
- DTI *see* diffusion tensor imaging (DTI)
- dual coding, mnemonics, 528
- dual task performance, executive/cognitive function rehabilitation, 472
- Dysexecutive Questionnaire (DEX)
  - attention assessment, 98
  - executive functions assessment, 99
- dyslexia, event-related potentials, 193
- EAA *see* excitatory amino acids (EAAs)
- early GABA-ergic activation study in stroke (EGASIS), 309
- ECG (electrocardiography), Alzheimer’s disease exercise training, 252
- ecological validity
  - cognitive activity assessment *see* cognitive activity assessment
  - outcome measures, 115
- ECT (electroconvulsive therapy), depression, 210
- Edinburgh Functional Communication Profile, 99
- education effects
  - intra-individual variability, 47
  - normal aging, 156, 157
- EEG *see* electroencephalography (EEG)
- efficacy (of therapy), 121
  - evaluation, cognitive neurorehabilitation, 569
  - phase II clinical trial, 85
  - phase III clinical trial, 86
  - rehabilitation research phase models, 82
- EGASIS (early GABA-ergic activation study in stroke), 309
- EGF *see* epidermal growth factor (EGF)
- elderly *see* age-related effects
- electrical brain stimulation, plasticity, 12, 16
- electrocardiography (ECG), Alzheimer’s disease exercise training, 252
- electroconvulsive therapy (ECT), depression, 210
- electroencephalography (EEG), 182, 183, 185–190
  - ADHD, 499
  - exercise/physical activity, 427
- electrolytes, homeostasis, 62
- electrophysiological studies, TBI effects, 509
- elevators, distal memory aids, 525
- eligibility criteria, methodological quality evaluation *see* methodological quality evaluation
- (S)-emopamil, 305
- emotional aspects
  - apathy, 212
  - memory impairment, 534–535
    - rehabilitation *see* memory rehabilitation, post-injury
  - post-TBI anosognosia therapy studies, 224
- emotional self-regulation training, 472
- emotion-focused coping, 235
- employment status, anosognosia therapy, 222
- encoding strategies, age-related memory rehabilitation, 545
  - encoding self-initiation, 542
- endogenous stem cells, neural stem cell therapy, 378
- endothelial nitric oxide synthase (eNOS), 261
- energization function
  - rehabilitation *see* frontal lobe functions, rehabilitation *see* frontal lobe functions
- energy balance
  - homeostasis *see* homeostasis
  - sedentary lifestyle, 70
- enriched housing
  - brain derived neurotrophic factor, 382
  - cognitive functions, 351, 381
  - fibroblast growth factor, 382
  - nerve growth factor, 382
  - neurogenesis, 379, 381
- environment
  - attention rehabilitation *see* attention, rehabilitation post-TBI
  - cognitive function enhancement, 311
  - memory rehabilitation, elderly, 545, 554
  - neurogenesis *see* neurogenesis
  - TBI in children, 489
- epidemiological studies, exercise/physical activity *see* exercise/physical activity
- epidermal growth factor (EGF)
  - neural stem cell therapy, 382, 383, 386
  - neurogenesis, 306
- epinephrine, TBI, 307
- episodic memory, 299
  - aging-related changes, 149, 152, 542, 543
  - Alzheimer’s disease, 542, 543
  - compensation, 31
  - focal brain lesion localization, 135
- ERFs *see* event-related fields (ERFs)
- ERPs *see* event-related potentials (ERPs)
- error awareness/self-monitoring *see* metacognitive function rehabilitation

- errorless learning  
   age-related memory rehabilitation, 552–553  
   Alzheimer's disease, 553  
   memory impairment rehabilitation *see* memory rehabilitation, post-injury  
   semantic memory rehabilitation, 533
- erythropoietin, neural stem cell therapy, 382, 383, 386
- stroke, 385
- estrogen(s), 66–68
- estrogen receptors (ERs), 66
- estrus cycle, 66
- état criblé, MRI, 143
- ethics  
   anosognosia neurorehabilitation, 220  
   single subject experimental methods, 328
- European Federation of Neurological Societies, 107
- event-related fields (ERFs), 192–194  
   cortical remodeling, 184  
   definition, 184  
   mismatch negativity, 190
- event-related potentials (ERPs), 122, 192–194  
   cortical remodeling, 184  
   definition, 184  
   exercise/physical activity, 427  
   mismatch negativity, 190  
   rapid time periods, 122
- everyday activities  
   cognitive neurorehabilitation, 570, 572  
   TBI vs. ADHD, 496
- Everyday Memory Questionnaire, 97
- evidence-based research/therapy, 81, 106–108  
   cognitive neurorehabilitation, 570  
   *see also* reviews (of cognitive rehabilitation)
- excision, plasticity, 12
- excitatory amino acids (EAAs), 303–304
- exclusion criteria, 112
- executive dysfunction, 264, 398  
   ADHD, 487  
   TBI vs., 496  
   Alzheimer's disease *see* Alzheimer's disease  
   cerebral hypoperfusion, 263–264  
   frontotemporal dementia, 250, 264–265  
   frontotemporal lobar degenerations, 336  
   pseudodementia, 209  
   TBI, 321, 487, 488  
   ADHD vs., 496  
   vascular dementia, 250, 264
- executive dysfunction, rehabilitation, 470, 471–472  
   pharmacological therapy, 313
- executive functions, 300, 464, 465–466, 487–506  
   assessment, 99  
   developmental perspective, 488  
   *see also* neural substrate *below*  
   dysfunction *see* executive dysfunction  
   exercise/physical activity, 250  
   longitudinal studies, 428  
   neural substrate, 298, 488–489  
   tests  
     coping, 235  
     reaction time tasks, 466  
     *see also specific executive functions*
- executive functions, children, 489–495
- Executive Plus, psychosocial factors, 245
- exercise/physical activity, 204, 250–271, 281, 397, 417–434  
   age-related memory rehabilitation, 549–550  
   angiogenesis *see* angiogenesis  
   cerebral blood flow, 245, 259  
   cognition, 351  
   fMRI, 427  
   intensity effects, 245  
   negative findings, 245  
     Activity of Daily Living, 259  
     aerobic activity changes, 259  
     Alzheimer's disease, 259  
     Instrumental Activity of Daily Living, 259  
     subcortical ischemic vascular dementia, 259  
   neurogenesis, 70, 379, 418, 421–422  
   observational studies, 423–426
- ex-Gaussian distributions *see* variability
- existing function optimization, age-related memory rehabilitation *see* memory rehabilitation, elderly
- exogenous stimulation *see* neural stem cell therapy
- Expanded Disability Status Scale, 93
- expanded rehearsal, memory impairment, 526, 529
- experience, age-related memory, 549
- experience dependent plasticity, Rothi's revision of the Robey model, 84
- explanatory optimism, 238
- explicit memory rehabilitation, 552
- explicit recall, errorless learning, 529
- Exploratory Clinical Study *see* Rothi's revision of the Robey model
- Extended Activities of Daily Living (EADL), 94
- external compensation, age-related memory rehabilitation, 554

- external cueing, behavioral/emotional function rehabilitation, 474
- external locus of control, psychosocial factors, 236
- external memory aids *see* memory rehabilitation, elderly
- extrapersonal neglect, neglect syndrome, 449
- eye patching, neglect syndrome rehabilitation, 458
- false negatives, functional imaging, 165
- familial cerebral amyloid angiopathy (fCAA), 366–368
- familial noncerebral amyloid angiopathy cerebral microangiopathies, 362
- familial syndromes of cerebral microangiopathy, 368–369
  - see also specific diseases/disorders*
- family anxiety, memory impairment rehabilitation, 535
- family history, depression, 208
- family input, memory impairment rehabilitation, 535
- fatigue, depression, 208
- feature integration reaction time tasks, dispersion, 51
- fed/fastened state, 281
- feedback training, neglect syndrome rehabilitation, 452
- FGF *see* fibroblast growth factor (FGF)
- FGF-2 *see* fibroblast growth factor-2 (FGF-2)
- fibroblast growth factor (FGF), 307, 382
- fibroblast growth factor-2 (FGF-2)
  - Huntington’s disease, 383
  - neural stem cell therapy, 382, 383, 386
  - stroke, 385
  - neurogenesis, 306
  - regeneration, 14
- FIM *see* Functional Independence Measure (FIM)
- fitness measures, epidemiological studies, 425
- 5HT *see* serotonin
- FLAIR *see* fluid attenuated inversion recovery (FLAIR)
- fluid attenuated inversion recovery (FLAIR)
  - cerebral microangiopathy, 369
  - MRI, 126, 138
- fluvoxamine, clinical trials, 342
- focal brain lesion localization *see* imaging
- focal cortical contusions, TBI, 321
- focal hand dystonia, magnetoencephalography, 194
- focal parenchymal injury, TBI, 469
- focused attention deficit, variability, 39, 40
- focused attention tasks, exercise/physical activity, 428
- focused training, selective attention rehabilitation, 513
- fractional anisotropy (FA), diffusion tensor imaging, 131, 134
- Freedox, 305
- free radicals, 305
- free recall, memory, aging effects, 542
- Frenchay Activities Index, 94
- frontal lobe(s), 464–486
  - damage
    - cognitive activity assessment, 96
    - inter-individual variability, 42
    - intra-individual variability, 43–46, 52
  - disorders, 398, 468–470
    - see also specific diseases/disorders*
  - functions *see below*
  - intra-individual variability, 49
  - lesions, dispersion, 51
  - normal aging, 151
    - functional imaging, 150, 156
  - subcortical circuits *see* frontal subcortical circuits
  - variability, 50
- frontal lobe functions, rehabilitation, 470–478
- frontal subcortical circuits, 205–206
- fronto-cortical circuits, white matter lesions, 263
- fronto-hippocampal circuits, white matter lesions, 263
- frontoparietal cortex, exercise/physical activity, 420
- fronto-striatal system, white matter lesions, 263
- frontotemporal dementia (FTD)
  - cerebral hypoperfusion, 263, 265
  - definition, 251
  - executive dysfunction, 264–265
  - executive functions, 250
  - exercise intervention studies, 256
  - gait disorders, 265, 266
  - vascular disease, 261
- frontotemporal lobar degenerations (FTLDs), 336
  - pharmacologic therapy, 342
  - symptoms, 336
    - see also specific diseases/disorders*
- frontotemporal Mild Cognitive Impairment (FT-MCI), 266
- fructose administration, 282
- FTD *see* frontotemporal dementia (FTD)
- FTLDs *see* frontotemporal lobar degenerations (FTLDs)
- Functional Assessment Measure (FAM), 95
- Functional Assessment of MS, 95
- Functional Assessment Staging scale (FAST), 341
- Functional Communication Profile, 99
- functional conversation skills, 440
- functional imaging, 121, 162–181, 566
  - applications, 122
    - ADHD, 489
    - executive functioning, 488
    - frontal lobe function rehabilitation, 478
    - Huntington’s disease, 208
  - depression *see* depression
  - intra-individual variability, 49

- functional imaging (cont.)
  - normal aging, 122, 149–161
  - Parkinson's disease, 207, 208
  - short-term changes, 149
  - see also specific methods*
- Functional Independence Measure (FIM)
  - activity assessment, 94
  - deficit awareness, 475
  - multiple sclerosis assessment, 95
- functional integration, adult neurogenesis, 348
- functional interactions, injury, 164
- functional localization, neurological recovery, 175
- functional magnetic resonance imaging (fMRI), 122
  - ADHD, 489
  - anosognosia treatment outcome measures, 226
  - aphasia recovery, 169
  - CIMT, 404, 405
  - compensation, 32, 33
  - depression assessment, 210
  - exercise/physical activity, 427
  - lesion-behavior analysis, 140
  - neurological recovery, 175
  - Patient Competency Rating Scale, 227
  - stroke, 122
  - TBI effects, 509
- funding
  - randomized clinical trials, 81
  - rehabilitation research, 79
- GABA, distribution, 309
- GABA-ergic neurons, adult neurogenesis, 350
- GABA-ergic system, executive functions, 300
- gait, cerebral hypoperfusion *see* cerebral hypoperfusion
- gait disorders, 265–266
  - MRI subcortical hyperintensities, 132
- galantamine
  - attention, 312
  - clinical trials
    - Alzheimer's disease, 340–341
    - vascular dementia, 343
- gene expression effects, docosahexaenoic acid, 279
- General Health Questionnaire
  - general psychological distress, 96
  - mood assessment, 96
- generalization
  - aphasia therapy, 442
  - mnemonics, 528
- generalized synaptic loss, frontotemporal lobar
  - degenerations, 336
- genetic–environment interactions, lesion-behavior
  - analysis, 141
- Genetic Evaluation by Relative's Rating Instrument (GERRI), 343
- genetics
  - neurogenesis models, 354
  - plasticity studies, 12
- ghrelin receptors, 68, 69
- ginkgo biloba, vascular dementia clinical trials, 343
- Glasgow Coma Scale, event-related potentials vs., 193
- glial cell(s)
  - adult neurogenesis, 348
  - corticosteroid receptors, 65
  - neural stem cell transplantation, 384
- glial cell line-derived neurotrophic factors, 306, 307
- glioblastomas, 469
- gliomas, 469
- globus pallidus, frontal subcortical circuits, 206
- glucocorticoid(s), 63, 64
- glucocorticoid receptor (GR), 64
  - expression reduction, 66
  - spatial learning, 66
- glucose
  - administration effects, 282, 283
  - age-related memory rehabilitation, 550
  - depletion effects, 282
- GLUT4 receptor, 69
- glutamate
  - Alzheimer's disease, 335
  - neurotoxicity, 303
  - restraint stress, 64
- glutamatergic system, estrogen receptors, 66
- glutamatergic system, executive functions, 300
- Goal Management Training (GMT)
  - attention rehabilitation *see* attention, rehabilitation
  - post-TBI
    - behavioral/emotional function rehabilitation, 473
- “goal neglect”, behavioral/emotional function
  - rehabilitation, 472
- goals, age-related memory rehabilitation, 544
- gonadal steroids, 66–68
- go/no-go performance, in children, post-TBI, 491
- Gordon Diagnostic System (GDS), attention
  - rehabilitation, 512
- GRADE working group, 109
- gradient echo imaging, MRI, 133
- grammatic impairment, phrase/sentence level treatment, 439
- “granular atrophy”, ischemic vascular disease, 362
- group effects, variability, 39

- group therapy, psychosocial factors, 243
- group variability, scatter *see* scatter
- guanfacine, neglect syndrome rehabilitation, 460
- Guttman scaling, activity assessment, 94
- Guys Neurological Disability Scale, 93
- Hair Combing Task, 98
- Halstead–Reitan Battery, 471
- Harmonization Consensus guidelines, MRI, 133
- head/trunk rotation, neglect syndrome rehabilitation, 455
- healthcare costs, aging, 568
- heart rate change, exercise, 259
- Helm Elicited Program for Syntax Stimulation (HELPSS), 439
- hemianopias, anosognosia, 219
- hemiblinding, neglect syndrome rehabilitation, 458
- hemiplegia, anosognosia, 218
- hemorrhagic stroke, 376
- HERNS, 362
  - definition, 369
- herpes encephalitis, 476
- “hidden costs”, compensation, 28
- higher cognitive functions
  - compensation, 28
  - coping, 235
- high glycemic index foods, 283
- high-involvement goal setting, behavioral/emotional
  - function rehabilitation, 473
- high quality fats, chronic diet, 272
- hippocampal sclerosis (HS), 364
- hippocampus
  - adult neurogenesis, 348
  - aging-related changes, 152
    - connections, 155
  - atrophy
    - glucocorticoids, 64
    - major depression, 64
    - post-traumatic stress disorder, 64
  - cerebral hypoperfusion, gait, 263
  - cognition, 351
  - Cushing’s disease, 64
  - focal brain lesion localization, 134
  - gonadal steroids, 67
  - insulin signaling, 274
  - memory, aging effects, 543
  - neurogenesis
    - exercise/physical activity, 421
    - training, 354
  - plasticity, 10
  - TBI, 321
  - hippocampus dentate gyrus, neurogenesis, 352
- history taking
  - apathy, 213
  - depression *see* depression
- HIV infection, pseudodementia, 209
- holistic methods
  - anosognosia treatment, 223, 226
  - memory impairment
    - rehabilitation, 534
- homeostasis
  - definition, 62
  - electrolytes, 62
  - energy balance, 62
    - peptide hormone receptors, 68
  - mediators, 62
- home practice (HP), constraint-induced movement
  - therapy, 412
- home skill assignment (HSA), constraint-induced
  - movement therapy, 411–412
- homocysteine
  - exercise and nitric oxide, 262
  - vascular dementia, 262
  - vascular disease, 261
- hormones, 62–78
- Hospital Anxiety and Depression Scale, 96
- “house-keeping” operations, neurological recovery from
  - injury, 162
- Huntington’s disease
  - animal models/studies, 384
  - fibroblast growth factor-2, 383
  - anxiety disorders, 211
  - depression, 208
  - functional imaging, 208
  - neurotrophic factors, exercise/physical
    - activity, 423
  - positron emission tomography, 208
  - stem cell therapy, 307
- 6-hydroxydopamine, Parkinson’s disease, 419
- hypercortisolemia, 64
- hyperpolarization-activated cyclic nucleotide-gated cation
  - channels, 301
- hypertension
  - chronic diet, 273
  - microvascular disease, 363
  - MRI subcortical hyperintensities, 132
- hyperthyroidism, apathy, 213
- hypoparathyroidism, apathy, 213
- hypoperfusion, cerebral *see* cerebral hypoperfusion
- hypothalamic-pituitary-gonadal (HPG) axis, 66

- hypothalamus, adult neurogenesis, 350  
 hypoxia-inducible factor (HIF), exercise/physical activity, 420
- IADL scale, deficit awareness, 475  
 idiopathic Parkinson's disease, 337  
 imaging, 3, 566  
   compensation, 28, 30–31  
   depression, 207  
   focal brain lesion localization, 134–141  
   functional *see* functional imaging  
   image acquisition, 137–138  
   lesion-behavior analysis, 140–141  
   plasticity, 182  
   rapid time periods, 122  
   spatial normalization, 138–139  
   stroke, 122  
   structural *see* structural imaging  
   volume information, 138  
   *see also specific methods*
- immune damage, secondary neurological diseases/disorders, 303  
 immunohistochemistry, ischemic vascular disease, 362  
 impaired self-awareness (ISA) *see* anosognosia  
 implicit learning, errorless learning, 528, 529  
 implicit memory, age-related memory rehabilitation, 551–553  
 in-built alarms, memory impairment rehabilitation, 526  
 inclusion criteria, 112  
   Rothi's revision of the Robey model, 85  
 inconsistency *see* variability  
 inflammation  
   central nervous system, 276  
   cerebral amyloid angiopathy, 365, 367  
   insulin resistance, 276–277  
   neurogenesis, 353  
   neurological diseases/disorders, 298  
   secondary neurological diseases/disorders, 303  
   type-2 diabetes mellitus, 276–277
- information sharing, cognitive neurorehabilitation, 573  
 infrastructure, neurogenesis, 353  
 inhibition, 490–491  
 inhibitory avoidance tasks, estrogen, 67  
 injury, neurological recovery, 162–163  
   experimental strategies, 163–164  
   “house-keeping” operations, 162  
   levels of organization, 162, 163  
   neurotransmitter receptors, 162  
   *see also* traumatic brain injury (TBI)  
 “inner speech”, 474  
 innovation stage  
   Rothi's multistage model, 4  
   Rothi's revision of the Robey model, 85  
 Institutional Review Boards, 328  
 Instrumental Activity of Daily Living, 259  
 insulin, 68, 69  
 insulin, signaling, 272, 273–278  
 insulin-like growth factor-1 (IGF-1), 277, 307  
   exercise/physical activity, 420  
   neural stem cell therapy, 382, 383  
   neurogenesis, 69  
   exercise/physical activity, 421  
 insulin receptors, 68, 69  
 insulin resistance (IR), 276  
   chronic diet, 273  
   dietary effects, 277–278  
   inflammation, 276–277  
   insulin signaling, 273, 274  
   lifestyle effects, 277  
   neurotrophins, 277  
   oxidative stress, 276–277  
 intact function substitution *see* memory rehabilitation, elderly  
 integration, cognitive neurorehabilitation, 566  
 integrative encoding *see* memory rehabilitation, elderly  
 integrity, treatment descriptions, 114  
 intelligence effects, intra-individual variability, 47  
 intentional systems, word level treatments, 438  
 intent-to-treat analysis, methodological quality evaluation, 115  
 interactive modeling training, executive/cognitive function rehabilitation, 471  
 interhemispheric imbalance correction, neglect syndrome *see* neglect syndrome rehabilitation  
 inter-individual variability, 41–43  
 internal locus of control, 236  
 internal validity, indicators, 110  
 International Classification of Functioning, Disability and Health (ICF), 87–88, 91  
 international clinical trials network, cognitive neurorehabilitation, 573  
 inter-rater reliability, definition, 92  
 intervention studies, exercise *see* exercise/physical activity  
 intracortical microstimulation studies, CIMIT, 404



- intra-individual variability, 43–46, 52
  - acquired focal brain damage, 48
  - affecting factors, 46–49
  - Alzheimer’s disease, 48
  - Attention Deficit Hyperactivity Disorder, 48
  - depression, 49
  - functional imaging, 49
  - Lewy body disease, 48
  - malinger, 39–41, 54
  - neurological disorders, 46, 48–49
    - see also specific diseases/disorders*
  - neuropsychiatric disorders, 49
    - see also specific diseases/disorders*
  - Parkinson’s disease, 48, 49
    - task factors, 47
  - population factors, 46, 47–48
  - progressive forms, 48
  - rehabilitation therapy, 53–54
  - schizophrenia, 49
  - situational factors, 46, 47
  - task factors, 46, 47
  - TBI, 48, 49
  - time scales, 43
  - vascular dementia, 48
- intra-rater reliability, definition, 92
- Iowa Gambling Task, 493
- IQ level effects, coping, 236
- irrelevant information, aging-related changes, 152
- ischemic stroke, 376
- ischemic vascular disease (IVD), 297, 360
  - astrocytes, 362
  - autopsy studies, 360
  - community-based investigations, 360
  - epidemiology, 361
  - “granular atrophy”, 362
  - lesions, 361, 362
  - microglia, 362
  - neuropathologic substrates/correlates, 361, 362–364
- isotropic diffusion, diffusion tensor imaging, 134
- IVD *see* ischemic vascular disease (IVD)
- kainate receptors, excitatory amino acids, 303
- Ki-67 expression, neurogenesis, 356
- Korsakoff’s syndrome, apathy, 213
- labeling, proximal memory aids, 524
- laboratory motor tests, CIMT efficacy, 406
- lactate, magnetic resonance spectroscopy, 133
- lacunar infarcts, ischemic vascular disease, 362, 363
- lacunes, MRI, 127, 143
- language
  - assessment, 99
  - cerebral location, 7
  - classification/subdivisions, 436
  - comprehension *see below*
  - disorders, phase II clinical trial, 86
  - learning, example of, 84
  - production therapy *see below*
  - reorganization, event-related potentials, 193
  - see also aphasia*
- language comprehension, 441–442
- language production therapy, 437–438, 572
  - phrase/sentence level treatment, 438–439
  - word level treatments, 437–438, 443
  - see also aphasia therapy*
- language system rehabilitation, 398
- lapse minimization, proximal memory aids, 525
- Last Observation Carried Forward (LOCF) analysis
  - clinical trials, Alzheimer’s disease, 341
  - memantine clinical trials, 341
- latent skill substitution, compensation, 26
- lateral orbital cortex, frontal subcortical
  - circuits, 206
- lateral prefrontal cortex (LPFC)
  - aging-related changes, 155
  - executive cognitive functions, 465
- lateral temporal cortex, memory, aging effects, 544
- laseroids, 305
- LCFS (Level of Cognitive Functioning Scale), 99
- learning
  - neurogenesis, 354, 356, 379
  - omega-3 fatty acids, 279
- left hemiplegia, anosognosia therapy outcome, 221
- left prefrontal cortex, memory, aging effects, 543
- left sided vestibular stimulation, neglect syndrome
  - rehabilitation, 456
- left superior temporal gyrus, aphasia recovery, 165
- left temporal cortex, aphasia recovery, 171
- legislation, Rothi’s revision of the Robey model, 86
- leisure activities, age-related memory rehabilitation, 549–550
- leptin, 68
  - antidepressant effects, 69
  - stress responses, 63
- leptin receptors, 68, 69
- lesion(s)
  - anterior cingulate cortex, 206
  - behavior analysis, imaging *see* imaging

- lesion(s) (cont.)
  - dorsolateral prefrontal, 206
  - frontal subcortical circuits, 206
  - ischemic vascular disease *see* ischemic vascular disease (IVD)
  - location, inter-individual variability, 42
  - masking, imaging spatial normalization, 138, 139
  - orbitofrontal circuit, 206
  - studies
    - animal models of plasticity, 12, 13
    - dispersion, 51
    - subtraction analysis, 140
- letter fluency tasks, executive/cognitive function rehabilitation, 472
- leukoaraiosis
  - ischemic vascular disease, 360, 362
  - MRI subcortical hyperintensities, 127, 130
- leukoencephalopathy, MRI subcortical hyperintensities, 127
- Level of Cognitive Functioning Scale (LCFS), 99
- levodopa
  - neglect syndrome rehabilitation, 459
  - pseudobulbar affect treatment, 211
- levodopa-carbidopa, attention therapy, 510, 512
- Lewy bodies
  - definition, 337
  - see also* dementia with Lewy bodies
- life history stage
  - allostasis, 63
  - diseases/disorders, 63
- lifestyle
  - exercise/physical activity, epidemiological studies, 424
  - insulin resistance, 277
- lifetime psychiatric disorders, TBI vs. ADHD, 495
- limb activation therapy, neglect syndrome rehabilitation, 453
- linear transformation, imaging spatial normalization, 139
- line bisection, neglect syndrome, 450
- Linguistic Specific Treatment (LST), 439, 442
- lipohyalinosis, ischemic vascular disease, 363
- listening exercise example, Rothi's revision of the Robey model, 84
- lithium, bipolar affective disorder, 211
- living conditions, adult neurogenesis, 349
- living situation effects, optimism, 239
- LLI example
  - phase II clinical trial, 86
  - Rothi's revision of the Robey model, 84, 85
- location detection devices, memory impairment rehabilitation, 530–531
- LOCF *see* Last Observation Carried Forward (LOCF) analysis
- locus ceruleus (LC), alpha-2-adrenergic receptors, 301
- locus of control *see* psychosocial factors
- London Handicap Scale, 100
- longitudinal studies
  - exercise/physical activity *see* exercise/physical activity
  - fMRI study, aphasia recovery, 170
  - neuroelectric recordings, 194
  - neurological recovery, 169
  - neuromagnetic recordings, 194
  - optimism, 238
- long-term follow-up studies, anosognosia therapy, 228
- long-term potentiation
  - brain-derived neurotrophic factor, 277
  - exercise/physical activity
    - neurogenesis, 421
    - neurotrophic factors, 422
  - insulin signaling, 275
- low glycemic index foods, 283
- LPFC *see* lateral prefrontal cortex (LPFC)
- LST (Linguistic Specific Treatment), 439
- Luria's verbal self-regulation, case study, 53
- magnesium ion blockade, excitatory amino acids, 303
- magnetic resonance imaging (MRI), 126, 163
  - amyloid angiopathy, 130, 144
  - cerebral microangiopathy *see* cerebral microangiopathy
  - clasmotodendrosis, 131, 144
  - depression, 207, 210
  - diffusion tensor imaging, 132
  - exercise/physical activity, 429
  - fluid attenuated inversion recovery, 126, 138
  - functional *see* functional magnetic resonance imaging (fMRI)
  - gradient echo imaging, 133
  - intensity differences, 126
  - introduction, 128
  - magnetization transfer imaging, 133
  - multiple sclerosis, 130, 144, 207
  - pathological changes, 126
  - proton density, 126
  - signal abnormalities, 143–144
  - standardized acquisition, 133
  - structural *see* structural magnetic resonance imaging
  - subcortical hyperintensities *see below*
  - T1-weighted imaging, T2 vs., 138
  - T2-weighted imaging, 133
    - quantitative, 132
    - T1 vs., 138

- three-dimensional, 135, 138
- two-dimensional, 135
- volumetric analysis
  - executive functioning, 488
  - TBI, 497
- magnetic resonance imaging (MRI), subcortical
  - hyperintensities, 126
- aging, 132
- attention disorders, 132
- cerebrovascular disease, 132
- clinical relevance, 132
- cognitive decline, 132
- gait disorders, 132
- historical overview, 127–131
- hypertension, 132
- mental processing speed, 132
- motor dexterity, 132
- quantification, 131–133
- magnetic resonance spectroscopy, 132, 133
- magnetization transfer (MT) imaging *see* magnetic resonance imaging (MRI)
- magnetization transfer ratio, 132
- magnetoencephalography (MEG), 122, 182, 183, 184–185, 194
- Mahalanobis distance, scatter, 46
- major depression, hippocampal atrophy, 64
- maladaptive behavior, 494
- malingerer *see* intra-individual variability
- mapping therapy, phrase/sentence level treatment, 439
- masked outcome trials, methodological quality
  - evaluation, 112
- maturation
  - adult neurogenesis, 348
  - rehabilitation research, 83
- mean arterial blood pressure change, exercise, 259
- mean effect size (MES), CIMT efficacy, 406
- “mechanism targeted” techniques, rehabilitation
  - research, 80
- medial prefrontal cortex (mPFC) lesions
  - animal models of plasticity, 14
  - plasticity, 14
- medial temporal areas, aging-related changes, 153, 155
- median-split partition, inter-individual variability, 42
- median temporal lobe, focal brain lesion localization, 134
- mediators, psychosocial factors, 234
- medical diseases/disorders
  - apathy *see* apathy
  - depression, 207
- MEG *see* magnetoencephalography (MEG)
- Melodic Intonational Therapy (MIT), 440, 441
- memantine, 341–342
- memory, 299, 313
  - adrenalectomy, 65
  - Alzheimer’s disease *see* Alzheimer’s disease
  - assessment, 97
  - corticosteroid effects, 65–66
  - corticosterone, 65, 66
  - Cushing’s disease, 66
  - in elderly *see* memory, aging effects
  - emotional aspects, 534–535
  - estrogen, 67
  - insulin signaling *see* insulin, signaling
  - measures, 93
  - neural substrate, 298
  - outcome measures, 114
  - post-injury rehabilitation *see* memory rehabilitation, post-injury
  - problems, 399
  - rehabilitation *see* memory rehabilitation
- memory, aging effects, 149, 541–543
- memory aids, 524–526
- Memory Compensation Questionnaire, 26
- Memory Failures Questionnaire, 97
- memory performance prediction, anosognosia therapy
  - outcome, 220, 221
- memory rehabilitation
  - language training, Alzheimer’s disease, 256
  - paging systems, 531
  - pharmacologic therapy, 312–313
- memory rehabilitation, elderly, 541–561
- memory rehabilitation, post-injury, 522–540
- meningiomas, 469
- mental fatigue, dispersion, 50
- mental imagery training, neglect syndrome
  - rehabilitation, 452
- mental processing speed, MRI subcortical
  - hyperintensities, 132
- mental slowness, attention rehabilitation *see* attention, rehabilitation post-TBI
- mental state examinations, depression, 209
- meta-analysis, longitudinal studies, 428
- metabolic syndrome, cognitive impairment, 276
- metacognition, 464, 467
  - anatomic principles, 465
  - developmental studies, TBI in children, 498
  - rehabilitation *see below*
- Metacognition Index, 495
- metacognitive function rehabilitation, 470, 475–476, 478

- methodological quality evaluation, 108–109  
   blinding, 112–113  
   controls, 113–114  
   eligibility criteria, 111–112  
   GRADE working group, 109  
   indicators, 108, 110  
   levels of evidence, 110  
   outcome measures, 114–115  
   randomization, 111  
   statistical analyses, 110, 115  
   treatment descriptions, 113–114
- methylphenidate, 301  
   attention, 312, 510, 512  
   executive functions, 313  
   memory, 313  
   TBI, 324  
     in children, 498  
   working memory, 313
- methylprednisolone, 305
- microangiopathy, cerebral *see* cerebral microangiopathy
- microbleeds, MRI subcortical hyperintensities, 131
- microglia, ischemic vascular disease, 362
- microinfarcts, ischemic vascular disease, 362
- middle cerebral artery, stroke, 468, 469
- Mild Cognitive Impairment (MCI)  
   age-related memory rehabilitation, 545  
   Alzheimer's disease *see* Alzheimer's disease  
   exercise effects, 250  
   pharmacological therapy *see* Alzheimer's disease,  
     pharmacological therapy  
   physical activity vs., 266
- mineralocorticoid(s), 63, 64
- mineralocorticoid receptor (MR), 64
- Mini-Mental State Examination (MMSE), 251  
   Alzheimer's disease, 262  
   exercise training, 252  
   cerebral microangiopathy, 370  
   clinical trials, vascular dementia, 343  
   dementia, 338, 339, 340  
   exercise intervention studies, 257  
   exercise/physical activity, 252, 257, 425
- minimization, variability, 41
- minimum-norm solutions, neuroelectric  
   recordings, 185
- Minnesota Leisure Time Questionnaire, 425
- mismatch negativity (MMN) *see* auditory  
   learning
- mixed vascular-Alzheimer's disease  
   dementia, 361
- MMSE *see* Mini-Mental State Examination  
   (MMSE)
- mnemonics, 399  
   age-related memory rehabilitation, 545, 546  
   post-injury memory rehabilitation *see* memory  
     rehabilitation, post-injury  
   semantic memory rehabilitation, 533
- mobile phones, memory impairment rehabilitation *see*  
   memory rehabilitation, post-injury
- models, compensation, 28
- moderators, psychosocial factors, 234, 239
- Modified Mini-Mental Status Examination, 338
- “moment-to-moment” variability, 43
- monoamine oxidase B inhibitors, 308
- mood, 203, 205–217  
   activity assessment, 94  
   frontotemporal lobar degenerations, 336  
   outcome measures, 95–96
- mood stabilizers, bipolar affective disorder,  
   210, 211
- morphometric studies  
   ADHD, 489  
   TBI in children, 489
- Morris water maze (MWM)  
   behavioral animal studies, 418  
   estrogen, 67  
   neurogenesis, 421
- Moss Attention Rating Scale (MARS), 98
- motivation, 203, 205–217
- motoractivity log (MAL), CIMT efficacy,  
   406, 411
- Motor Assessment Scale, 93
- motor competence, neurological recovery, 169
- motor cortex  
   exercise/physical activity, 420  
   neurological recovery, 166, 167
- motor dexterity, MRI subcortical hyperintensities, 132
- motor neglect, neglect syndrome, 449
- motor reorganization, neurological recovery, 166
- motor symptoms, Parkinsonism, 336
- motor system upregulation, neurological  
   recovery, 167
- MRI *see* magnetic resonance imaging (MRI)
- MS Impact Scale, 100
- multifactorial memory training programs, 546
- multilevel integration *see* cognitive neurorehabilitation
- multiple cognitive problems, memory, 536
- multiple group studies, 42
- multiple level domains, 87

- multiple sclerosis
  - activity assessment, 95
  - assessment
    - Assessment of Motor and Process Skills, 95
    - Functional Assessment of MS, 95
    - Functional Independence Measure, 95
  - depression *see* depression
  - magnetization transfer imaging, 133
  - MRI, 130, 144, 207
  - pseudodementia, 209
- myoinositol, magnetic resonance spectroscopy, 133
- naloxone, 310
- name, face pairs, elderly memory rehabilitation, 552
- names
  - memory impairment rehabilitation, 527
  - objects, neglect syndrome, 450
  - word level treatments, 437
- National Cancer Institute, rehabilitation research phase models, 82
- N-back task, working memory in children, post-TBI, 490
- neck/back pain therapy, methodological quality evaluation, 109
- neck muscle vibration (NMV), neglect syndrome rehabilitation, 455, 571
- necrosis
  - intracellular calcium ions, 304
  - secondary neurological diseases/disorders, 303
- neglect-alerting device, 454
- neglect syndrome, 571
  - anosognosia, 449
  - bedside tests for, 450
  - cognitive defects, 450
  - extrapersonal neglect, 449
  - lesion heterogeneity, 449, 460
  - motor neglect, 449
  - nonspatial mechanisms, 451
  - peripersonal neglect, 449
  - personal neglect, 449
  - rehabilitation *see below*
  - spatial mechanisms, 450
  - unilateral brain injury, 449
- neglect syndrome rehabilitation, 449–463
- neonatal injury models, neural stem cell therapy, 386
- nerve growth factor (NGF), 307
  - enriched housing effects, 382
- nerve growth factor family, 306
  - see also specific types*
- neural activity measurement *see* auditory learning
- neural axis activation, executive functioning, 489
- neural compensation, compensation, 26
- neural correlates
  - memory in elderly *see* memory, aging effects
  - spatial neglect recovery *see* spatial neglect recovery
- neural networks, TBI, 322
- neural pathway identification, psychosocial factors, 244
- neural recruitment drawbacks, compensation, 31
- neural shock, CIMT, 402
- neural stem cells (NSCs), 378–379
- neural stem cell therapy, 296, 307, 376–393
- neural structure effects, corticosteroids, 64–65
- neural substrate, 298–302
- neuritic plaques (NPs), Alzheimer’s disease, 334
- Neurobehavioral Functioning Inventory, 100
- Neurobehavioral Rating Scale, 100
- neurochemistry, 298–302
  - see also specific components*
- neuroelectric recordings, 182–199
- neuroelectric source imaging, CIMT, 404
- neurofibrillary tangles, Alzheimer’s disease, 334
- neurogenesis, 296, 348–359
  - adrenalectomy, 65
  - in adult, 348–351, 378, 379
  - aging vs., 381
  - androgens, 68
  - cognition, 351, 381
  - compensation, 30
  - corticosteroids, 65
  - dentate gyrus, 65
  - dietary restriction, 70
  - environmental manipulations, 377, 379–382, 387
  - exercise/physical activity *see* exercise/  
physical activity
  - fibroblast growth factor, 382
  - gonadal steroids, 66
  - human applicability, 356–358
  - IGF-1, 69
  - markers, 349
  - pharmacological therapy, 306
  - in regeneration, 352–353
  - stages, 350
  - stress, 65
  - therapeutic potential, 353–356
- neurogenin-2 expression, 384
- neuroimaging *see* imaging
- neurokine family, 306
  - see also specific types*

- neurological diseases/disorders
  - activity vs., 327
  - behavior spectrum classification, 311
  - commonalities, 298
  - measures, 93–94
  - neuropathology, 298
  - prevalence, 298
  - secondary, 303
  - therapy, classification, 310
  - see also specific diseases/disorders*
- neurological recovery, 166–169
- neuromagnetic recordings, 182–199
- neuronal growth, high-fat diets, 277
- neuronal networks, age-related plasticity, 13
- neuronal signaling cascades, high-fat diets, 277
- neuron replacement, neural stem cell therapy, 386
- NeuroPage, paging systems, 531
- neuropathic pain (allodynia), neural stem cell transplantation, 384
- neuropathology
  - insulin signaling *see* insulin, signaling
  - TBI *see* traumatic brain injury (TBI)
- neuroplasticity *see* plasticity
- neuroprotectin D1, 279
- neuroprotective molecules, 303, 304
  - exercise/physical activity, 418
- neuropsychiatric disorders, intra-individual variability, 49
- Neuropsychiatric Inventory (NPI)
  - clinical trials, 342
  - frontotemporal lobar degenerations, 342
  - mood assessment, 96
- neuropsychological functioning studies, outcome measures, 114
- Neuropsychological Test Battery, 338
- neurorehabilitation research, 79–90
  - animal models of plasticity, 15
  - evaluation, 106–118
  - see also* Rothi's revision of the Robey model
  - outcome measures, 79, 87–88
  - phase models, 81–82
  - randomization, 111
  - see also* clinical trials
- neurotoxicity
  - aspartate, 303
  - glutamate, 303
- neurotransmission, high-fat diets, 277
- neurotransmitter(s), 295
  - frontal subcortical circuits, 206
  - neurogenesis, 354
  - TBI *see* traumatic brain injury (TBI)
  - working memory, 299
  - see also specific neurotransmitters; specific systems*
- neurotransmitter receptors, injury, 162
- neurotrophic factors
  - exercise/physical activity *see* exercise/physical activity
  - neurogenesis, 382
  - see also specific factors*
- neurotrophin(s)
  - families, 306
  - high-fat diets, 277
  - insulin resistance, 277
  - insulin signaling, 277
  - in pharmacologic therapy, 306–307
  - see also specific types*
- neurotrophin 3 (NT3), 307
- neurotrophin 4 (NT4), 307
- “neurovascular coupling”, functional imaging, 164
- new group construction, inter-individual variability, 42
- new learning
  - memory impairment rehabilitation *see* memory rehabilitation, post-injury
  - mnemonics, 528
  - semantic memory rehabilitation, 533
- new skill substitution, compensation, 26
- nicotine, plasticity in rehabilitation, 15
- nicotinic acetylcholine receptors, Alzheimer's disease, 335
- nitric oxide, 261–262
- NMDA receptor(s), excitatory amino acids, 303
- NMDA-receptor agonists, neurogenesis, 306
- NMDA-receptor antagonists
  - excitatory amino acids, 304
  - Parkinson's disease, 341
- noise cancellation, magnetoencephalography, 185
- noncognitive skills, executive functioning, 487
- non-design factors, methodological quality evaluation, 108
- nonlinear transformation, imaging spatial normalization, 139
- non-mnemonic methods *see* memory rehabilitation, elderly
- non-neuronal growth factor family, 306
  - see also specific types*
- non-stationarity, variability, 44–45
- noradrenergic compounds, neglect syndrome, 460
- noradrenergic function, 301–302
- norepinephrine
  - Parkinson's disease, 337
  - TBI, 322
- normal aging, memory *see* memory, aging effects

- normalization, neurological recovery *see* neurological recovery
- notebooks, age-related memory rehabilitation, 554
- Nottingham Extended Activities of Daily Living, 94
- nucleus accumbens (NAcc), plasticity, 14
- number sequences, age-related memory rehabilitation, 547
- nutrition *see* diet/nutrition
- obesity, Zucker rat model, 69
- object encoding, aging-related changes, 155
- object-integrated aids *see* memory rehabilitation, post-injury
- object names, semantic memory rehabilitation, 533
- object recognition, TBI effects, 508
- observational studies
  - exercise/physical activity *see* exercise/physical activity
  - methodological quality evaluation, 109
- occurrence rates, methodological quality evaluation, 109
- omega-3 fatty acids, 278–279
- opiate kappa receptor antagonists, 310
- opiate peptide modulation, in injury/repair, 310
- optimism *see* psychosocial factors
- optokinetic stimulation, neglect syndrome rehabilitation, 456
- orbitofrontal circuit *see* frontal subcortical circuits
- orbitofrontal cortex (OFC), plasticity, 11
- organic cognitive impairment *see* compensation
- orienting system, attention, 299
- orphan drugs, TBI, 330–331
- outcome measures, 5, 91–92
  - activity, 91, 94–96
  - cognitive activity limitations *see* cognitive activity assessment
  - cognitive neurorehabilitation, 573
  - cognitive tests, 92
  - future work, 100–101
  - methodological quality evaluation *see* methodological quality evaluation
  - mood *see* mood
  - participation *see* participation
  - randomized controlled trials, 101
  - rehabilitation research *see* neurorehabilitation research
  - selection of, 92–93
  - short-term, 115
  - social/occupational activities, 100
  - TBI in children, 498
  - validation, cognitive neurorehabilitation, 566
- outcomes, 91–105
  - anosognosia therapy *see* anosognosia
  - comprehensive day treatment program studies, 240
  - single subject experimental methods, 328
- outlying observations *see* variability
- overactivation persistence, neurological recovery, 166
- overcoming learned non-use, CIMT, 402–404
- oxidative stress
  - insulin resistance, 276–277
  - type-2 diabetes mellitus, 276–277
- PACE, verbal fluency, 440
- Paced Auditory Serial Attention Task (PASAT)
  - attention rehabilitation, 515
  - executive/cognitive function rehabilitation, 472
- paging systems *see* memory rehabilitation, post-injury
- parahippocampus, aging-related changes, 152
- cortex, 153
- parenchymal lesions, ischemic vascular disease, 360
- parent interviews, everyday activities in children, post-TBI, 495
- Parkinsonism
  - Lewy bodies, 337
  - motor symptoms, 336
- Parkinson's disease
  - animal models, 384
  - exercise effects, 419
  - depression, 207, 208
  - functional imaging, 207, 208
  - 6-hydroxydopamine administration, 419
  - idiopathic, 337
  - intra-individual variability, 48, 49
  - task factors, 47
  - neurotrophic factors
    - exercise/physical activity, 423
    - glial cell-lined derived *see* glial cell line-derived neurotrophic factors
  - pathology, 336–337
    - aging-related changes, 156
  - pharmacologic therapy
    - clinical trials, 342–343
    - NMDA-receptor antagonists, 341
  - stem cell therapy, 307
- paroxetine, clinical trials, 342
- partial cues, elderly memory rehabilitation, 552
- participant characteristics, eligibility criteria, 112
- participant numbers, methodological quality evaluation, 115
- PASAT *see* Paced Auditory Serial Attention Task (PASAT)
- passive avoidance tasks, behavioral animal studies, 419

- passive listening, mismatch negativity, 190  
 passivity, Alzheimer's disease, 264  
 Patient Competency Rating Scale (PCRS), 227–228  
 patient compliance, anosognosia  
   neurorehabilitation, 223  
 patient identification, 477  
 patient–patient comparisons, focal brain lesion  
   localization, 136  
 peak capacity, cognitive function enhancement, 311  
 peptide hormone(s), 68–69  
   *see also specific hormones*  
 peptide hormone receptors, 68  
 perceptual learning, 186–191  
   definition, 183  
   *see also auditory learning*  
 perceptual sensitivity, TBI effects, 509  
 perceptual training, event-related potentials, 193  
 performance  
   cognitive function, 573  
   single subject experimental methods, 329  
 “performance oscillations”, variability, 39  
 “performance” tests, language assessment, 97  
 performing an action, age-related memory  
   rehabilitation, 547  
 peripersonal neglect, 449  
 perisylvian cortex, aphasia recovery, 170  
 periventricular white matter hyperintensities (PVWMH),  
   128, 143  
 periventricular white matter lesions, 263  
 personal activities of daily living, 94  
 personal digital assistants, 530  
 personal factors, 232  
 personality effects  
   coping, 236  
   frontotemporal lobar degenerations, 336  
 personal neglect, 449  
 PET *see* positron emission tomography (PET)  
 pharmacologic therapy, 298–320  
   *see also specific diseases/disorders; specific drugs/*  
   *treatments*  
 phase I clinical trials, 4  
 phase II clinical trials, 4  
 phase III clinical trials, 4  
 phase models, rehabilitation research *see*  
   neurorehabilitation research  
 phenytoin, TBI, 323  
 phlebotomy, rehabilitation research, 80  
 phobias, compensation, 24  
 phoneme level, word level treatments, 437  
 phospholipases, intracellular calcium ions, 304  
 phrase level treatment *see* language production therapy  
 physical activity *see* exercise/physical activity  
 physical fitness  
   age-related memory rehabilitation, 549–550  
   *see also exercise/physical activity*  
 physiological dysfunctions, neurological recovery,  
   167, 175  
 physiological stimuli, neurogenesis, 354  
 physiotherapy, neurogenesis, 355, 356  
 PI3K/Akt signal transduction  
   docosahexaenoic acid, 279  
   polyphenols, 279  
 Pick bodies, 336  
 Pick's disease, pathology, 336  
 pitch discrimination tests *see* neuroelectric recordings;  
   neuromagnetic recordings  
 planimetric tracing methods, structural  
   neuroimaging, 124  
 planning *see* problem-solving/planning  
 plasticity, 3, 6–21  
   codeine and amphetamine regulated transcript, 68  
   cognition, 351  
   imaging, 182  
   insulin signaling, 275  
   lesion-behavior analysis, 141  
   neural stem cell therapy, 386  
   neurological recovery, 175  
   pharmacologic therapy, 306  
   rehabilitation research, 80  
 points of translation, rehabilitation research, 79  
 polyphenols *see* dietary antioxidants  
 population factors, intra-individual variability *see* intra-  
   individual variability  
 population selectivity, eligibility criteria, 111  
 Porteus Maze test, 492  
 positron emission tomography (PET), 163  
   ADHD, 489  
   anosognosia, 221  
   anosognosia treatment, 226  
   aphasia recovery, 169  
   CIMT, 404  
   compensation, 30, 31  
   depression, 207, 208  
   depression assessment, 210  
   Huntington's disease, 208  
   lesion-behavior analysis, 140  
   Parkinson's disease, 207  
 posterior cortex, executive functioning, 488



- postmortem studies, “mild cognitive impairment”, 335
- post-stroke nonfluent aphasia, compensation, 32
- post-traumatic amnesia (PTA)
  - anosognosia therapy outcome, 221
  - TBI, 322
- post-traumatic stress disorder (PTSD)
  - hippocampal atrophy, 64
  - TBI in children, 489
- postural control, prism adaptation, 456
- practical aspects, single subject experimental methods, 328–330
- practical clinical trials (PCTs), 113
- practicality, outcome measures, 92
- practical tasks, visual neglect assessment, 98
- practice
  - age-related memory rehabilitation, 549
  - intra-individual variability, 47
  - outcome measures, 92
- predicted task performance, deficit
  - awareness, 475
- predictors, psychosocial factors, 234
- prefrontal cortex (PFC)
  - alpha-2-adrenergic receptors, 301
  - executive functions, 300
  - memory, aging effects, 543
  - subregions, executive functioning, 488
- prenatal stress, plasticity, 14
- primary apathy, 212
- primary prevention
  - pharmacological therapy, 302–303, 314
  - stroke, 302
  - substance abuse, 303
  - TBI, 302
- primary progressive aphasia (PPA), 336
- primate studies
  - CIMT, 402, 403
  - neglect syndrome rehabilitation, 459
- prior experience, plasticity, 14
- prism adaptation *see* neglect syndrome rehabilitation
- Problems in Everyday Living Questionnaire, 97
- problem-solving/planning
  - behavioral/emotional function rehabilitation, 473
  - in children, 492
  - coping, 235
  - executive/cognitive function rehabilitation *see* executive dysfunction, rehabilitation
  - executive functions assessment, 99
- procedural memory
  - age-related memory rehabilitation, 551–553
  - Alzheimer’s disease, 543
- process, definition, 91
- professional development/training, cognitive neurorehabilitation, 573
- Profile of Functional Impairment in Communication, 99
- progesterone, 67
- progressive disorders
  - intra-individual variability, 48
  - pharmacological therapy, 302
  - see also specific diseases/disorders*
- progressive supranuclear palsy (PSP), 336
- prolactin, neural stem cell therapy, 382, 383
- prompts, word level treatments, 437
- prosopagnosia, semantic memory rehabilitation, 533
- prospective aids, proximal memory aids, 525
- prospective memory, aging effects, 542
- protease activity modulators, 305–306
- protective safety mitt, CIMT, 410
- proton density (PD), MRI, 126
- proximal memory aids *see* memory rehabilitation, post-injury
- pseudobulbar affect, 211
- pseudodementia *see* depression
- psychiatric disorders, aging-related changes, 156
- psychoactive drugs, plasticity, 10, 14
- psychological tests, impairment measures, 93
- psychomotor activation programme (PAP), 258
- psychomotor stimulants, plasticity in rehabilitation, 15
- psychopharmacology, ADHD, 499
- psychosocial factors, 204, 232–241
- psychosocial training, psychosocial factors, 243
- psychostimulants, apathy, 213
- psychotherapy
  - apathy, 213
  - attention rehabilitation *see* attention, rehabilitation
  - post-TBI
  - depression, 210
  - memory impairment rehabilitation, 536
  - psychosocial factors, 243
- PTA *see* post-traumatic amnesia (PTA)
- PTSD *see* post-traumatic stress disorder (PTSD)
- public policy effects, Rothi’s revision of the Robey model, 86
- pyramidal cells, plasticity, 17
- quality of life measures, 91, 92
  - dementia intervention studies, 338
  - participation assessment, 100

- quality of practice, aphasia therapy, 444
- quantitative magnetic resonance imaging, cerebral
  - microangiopathy, 369
- quetiapine, bipolar affective disorder, 211
- quinidine, pseudobulbar affect treatment, 211
- Rancho Los Angeles Scale, 99
- randomization
  - exercise/physical activity longitudinal studies, 427
  - methodological quality evaluation *see* methodological quality evaluation
- randomized clinical trials (RCTs), 4, 81, 107
  - neglect-alerting device, 454
  - neglect syndrome rehabilitation, 451
  - outcome measures *see* outcome measures
  - requirements of, 82
  - tele-rehabilitation, 242
  - treatment efficacy, 82
  - visual scanning, 452
  - see also specific drugs*
- raphe nucleus, 336
- Rating Scale of Attentional Behavior, 98
- rating scales, MRI subcortical hyperintensities, 131
- rat models/studies
  - exercise/physical activity, 420
  - stroke models, 378
- RBMT *see* Rivermead Behavioral Memory Test (RBMT)
- reaction time (RT)
  - energization functions, 466
  - executive cognitive functions, 466
  - variability, 39
- reactive oxygen species (ROS), 305
- recognition memory, age-related memory
  - rehabilitation, 546
- recognition tasks
  - aging-related changes, 155
  - compensation, 30
- recollection
  - age-related memory rehabilitation, 548–549
  - definition, 548
- recruitment
  - randomized controlled trials, 101
  - rehabilitation research, 79
- regional metabolic glucose metabolism, aphasia, 170
- rehabilitation *see* neurorehabilitation
- “rehabilitation probe” experiments, 471
- rehearsal
  - aging-related changes, 151
  - techniques, 537
- relational views, psychosocial factors, 233
- relaxation therapy, 535
- reliability, outcome measures, 92
- remediation
  - compensation, 26
  - organic cognitive impairment, 29
- reminiscence therapy, dementia, 257
- remote memory cueing, 524
- reorganized activity, aphasia, 170
- repeated crossover design, 328
- repetitive task-oriented training *see* constraint-induced movement therapy (CIMT)
- repetitive transcranial magnetic stimulation (rTMS), 458
- repinotan, 310
  - phase I clinical trials, 310
  - phase II clinical trials, 310
- residential homes, distal memory aids, 525
- Response Elaboration Training (RET), 440, 441
- response time distributions, variability, 45
- restorative care, community-based interventions, 241
- restraint stress, glutamate release, 64
- retention effects, aphasia therapy, 443
- reviews (of cognitive rehabilitation), 107–108
- right hemisphere
  - hypodensity, computerised tomography, 137
  - recruitment, aphasia recovery *see* aphasia
  - stroke, anosognosia therapy outcome, 220
- risperidone, bipolar affective disorder, 211
- rivastigmine
  - attention, 312
  - clinical trials
    - Alzheimer’s disease, 340
    - dementia with Lewy bodies, 342
    - frontotemporal lobar degenerations, 342
- Rivermead Behavioral Memory Test (RBMT)
  - cognitive activity assessment, 96, 97
  - language assessment, 97
- Rivermead Head Injury Follow-Up Questionnaire, 95
- Rivermead Motor Assessment, 93
- Robey’s five-phase model, 82
- rotational forces, TBI, 507
- Rothi’s multistage model, 4
- Rothi’s revision of the Robey model, 82, 85
- running, neurogenesis, 356
- SART *see* Sustain Attention and Response task (SART)
- saturated fats, diet/nutrition, 280
- scanning board, neglect syndrome rehabilitation, 454

- scatter, 41, 46
  - clinical implications, 51
  - group variability, 52
  - mechanism, 50
- schizophrenia
  - intra-individual variability, 49
  - plasticity, 17
- school breakfast programs, 281
- schooling, age-related memory rehabilitation, 549
- secondary apathy, 212
- secondary emotional disturbances, TBI in children, 489
- sedatives, TBI, 323
- sedentary lifestyle, energy balance, 70
- selective attention
  - neglect syndrome, 451
  - TBI effects, 509
- selective attention rehabilitation *see* attention, rehabilitation post-TBI
- selective serotonin reuptake inhibitors (SSRIs)
  - apathy, 213
  - clinical trials, 342
  - depression, 207, 210
  - pseudobulbar affect treatment, 211
- selegiline, energization function rehabilitation, 474
- self-alerting, attention rehabilitation, 510
- self-awareness
  - impaired *see* anosognosia
  - self-efficacy, 237
- self-efficacy *see* psychosocial factors
- self-generated strategies *see* memory rehabilitation, elderly
- self-harm, depression, 208
- self-instructional techniques, Brief Mindfulness Training, 511
- self-limiting beliefs, psychosocial factors, 233
- self-monitoring
  - attention rehabilitation, 508–510
  - verbal fluency, 440
- self-monitoring training (SMT), error awareness/self-monitoring, 476
- self-pointing measure, 490
- self-referential processing, age-related memory rehabilitation, 547–548
- self-regulation
  - compensation *see* compensation
  - frontal lobe functions, 464
- semantic cueing treatment (SCT), 438
- semantic dementia (SD), 336
- semantic elaboration *see* memory rehabilitation, elderly
- semantic encoding, aging-related changes, 150
- semantic feature analysis (SFA), 438
- semantic memory
  - aging effects, 150, 542, 543, 544
  - Alzheimer's disease, 543
  - anomia, 533
  - compensation, 31
  - definition, 532
  - rehabilitation, 532–534
- semantic networks, word level treatments, 438
- semantic processing, aging-related changes, 151
- semi-automated image segmentation, 429
- senile plaques (SPs), Alzheimer's disease, 334
- sensitivity, outcome measures, 92
- sensory impairment, impairment measures, 93
- sensory motor representation topography *see* neurological recovery
- sensory selective attentional system, 508
- sentence level training *see* language production therapy
- serial correlation, variability, 44
- serotonergic system, executive functions, 300
- serotonin
  - frontal subcortical circuits, 206
  - Parkinson's disease, 337
  - TBI, 322
- serotonin 1a (5HT1a) receptor, 309
- serotonin 1a (5HT1a) receptor agonists, 310
- serotonergic system dysfunction, 262
- sertraline, 475
- Severe Impairment Battery (SIB), 338
- sexual-dimorphic responses, plasticity, 14
- Shapes Task, 98
- shaping, CIMT, 407, 408
- shearing strains, TBI, 507
- shield rooms, magnetoencephalography, 185
- shifting
  - in children, 491–492
  - definition, 491
- Short Form 5, 100
- short-term memory
  - aging effects, 542
  - Alzheimer's disease exercise training, 252
- Sickness Impact Profile, 95
- signal-to-noise ratio, neuroelectric recordings, 186
- signal transduction effects, polyphenols, 279
- signs, distal memory aids, 525
- simple discrimination tasks, visual evoked responses, 191
- Simulated Real Life Tasks (SRLTs), 473
- single-case design, outcome measures, 92
- single cell recordings, 182
- single level therapies, aphasia therapy, 444

- single-photon excitation computerized tomography (SPECT), vascular dementia, 263
- single subject experimental methods, 326
  - blind multiple cross-over trials, 329
  - data storage/analysis, 329
  - ethics, 328
  - Institutional Review Boards, 328
  - outcomes, 328
  - performance data, 329
  - practical aspects, 328–330
  - TBI therapy, 326–328
- situational factors *see* intra-individual variability
- SIVD *see* subcortical ischemic vascular dementia (SIVD)
- skewed distributions, 45
- skills, age-related memory rehabilitation, 553
- SMA, aphasia recovery, 171
- social control variables, 234
- social engagement, apathy, 212
- social experiences, plasticity, 10
- social history, depression, 208
- social interventions, apathy, 213
- social isolation, memory impairment
  - rehabilitation, 534
- social skills training, 243
- social support, 70
- society effects, outcome measures, 87
- somatosensory deficits, 456
- somatosensory evoked responses, 192
- somatosensory processing, event-related potentials, 194
- songbird high vocal center (HVC), androgens, 68
- sonic hedgehog, neurogenesis, 306
- source analysis, neuroelectric recordings *see* neuroelectric recordings
- source memory
  - aging-related changes, 149
  - compensation, 30
  - errorless learning, 529
- spaced retrieval (SR)
  - age-related memory rehabilitation, 551–552
  - Alzheimer's disease, 551
  - explicit memory rehabilitation, 552
  - word level treatments, 438
- space remapping training, 458
- space-representation alteration *see* neglect syndrome
  - rehabilitation
- spatial gradient of attention, 451
- spatial learning, glucocorticoid receptor, 66
- spatial mechanisms, neglect syndrome *see* neglect syndrome
- spatial memory tasks, neurogenesis, 381
- spatial neglect, 398
  - behavioral dissociations, 172
  - prevalence, 172
- spatial neglect recovery
  - bi-hemispheric acute suppression, 172–173
  - blood oxygen level dependent signal, 174
  - chronic reactivation, 172–173
  - functional connectivity breakdown, 174
  - interhemispheric imbalance, 173–174
  - neural correlates, 169–171, 172–174
  - over-activation, 173
  - “push-pull” imbalance, 173
  - sensory signals, 173
  - sub-acute stage, 172
- spatial normalization
  - imaging *see* imaging
  - lesion-behavior analysis, 140
- spatial working memory, 300
  - in children, post-TBI, 490
  - neglect syndrome, 451
- specific skill training, selective attention
  - rehabilitation, 512
- spine density, plasticity, 11
- stability, coping, 236
- standard deviation
  - scatter, 46
  - variability, 44
- Statistical Parametric Mapping (SPM), 138
- statistics
  - inter-individual variability, 42
  - methodological quality evaluation *see* methodological quality evaluation
  - overlap methods, focal brain lesions, 137
- stem cell therapy *see* neural stem cell therapy
- steroid therapy, Cushing's disease, 70
- stimulus dependency, plasticity, 16
- stop signal reaction time task, TBI vs. ADHD, 496
- stress
  - chronic
    - amygdala, 65
    - CA3, 64
    - corticosteroids, 64
    - corticosterone, 64
  - cocaine and amphetamine regulated transcript, 63
  - hormones, 63
  - insulin, 63
  - leptin, 63
  - neurogenesis, 65

- striatum
  - adult neurogenesis, 350
  - exercise/physical activity, 420
  - frontal subcortical circuits, 206
  - plasticity, 10
- stroke, 468
  - aging-related changes vs., 154
  - animal models, 378
  - anosognosia therapy outcome, 221
  - classification, 376
    - Barthel Index, 94
  - deficits, 377
    - dementia *see* vascular dementia (VaD)
    - depression, 207
  - dorsolateral stroke syndrome, 468
  - epidemiology, 125, 401
  - etiology
    - anterior cerebral artery aneurysms, 468, 469
    - anterior communicating artery, 468, 470
    - frontal lobe disorder, 468
    - middle cerebral artery, 468, 469
  - imaging, 122
    - see also specific methods*
  - incidence, 371
  - neurologic recovery, 162, 166, 371
  - plasticity, 12
  - primary prevention, 302
  - reviews, 107
  - subcortical, 168
  - therapy
    - amphetamines, 308
    - CIMT, 377
    - combinations, 377
    - community-based interventions, 241
    - diazepam, 309
    - effectiveness evidence, 107
    - event relevance, 17
    - methodological quality evaluation, 109
    - neural stem cell therapy *see* neural stem cell therapy
    - physiotherapy, 356
    - psychosocial factors, 233
    - rehabilitation therapy, 377
    - tissue plasminogen activator, 377, 387
      - see also* cerebral small vessel disease; cerebrovascular disease
  - Stroke Aphasic Depression Questionnaire, 96
  - “stroke-induced neurogenesis”, 362
  - Stroop Color Word and Trail Making, 98
- structural equation modeling analysis, exercise/physical activity, 424
- structural imaging, 124–148
  - memory impairment rehabilitation, 532
- structural magnetic resonance imaging, 121
  - exercise/physical activity, 427
- structured teaching, memory impairment rehabilitation, 522
- study comparisons, intra-individual variability, 43
- study time, age-related memory rehabilitation, 549
- subcortical ischemic vascular dementia (SIVD), 260
  - exercise, negative findings, 259
  - gait disorders, 266
- subcortical strokes, neurological recovery, 168
- subcortical structure, executive functioning, 488
- subjective bias, research evaluation, 106
- Subjective Memory Assessment Questionnaire, 97
- “subsequent memory effect”, aging-related changes, 153
- substance abuse, 303
- substantia nigra, frontal subcortical circuits, 206
- substitution, organic cognitive impairment, 29
- subventricular zone (SVZ), neurogenesis, 378, 379
- suicidal thoughts, depression, 208
- superconducting quantum interference devices (SQUID), 185
- supplementary motor area, aphasia recovery, 171
- surrogate markers, plasticity, 7
- Sustain Attention and Response task (SART)
  - attention, 508
  - TBI effects, 509, 510
- sustained attention, neglect syndrome, 451, 453
- Symbol Digit Modalities test, 508
- synaptic organization, pharmacologic therapy, 306–307
- systematic reviews (of cognitive rehabilitation), 108
- tacrine, clinical trials, 339
- tactile stimulation, plasticity, 15
- Talairach stereotactic coordinate system, 140
- TAP program, 440
- targeted remediation programs, 476
- task banks, CIMT, 408
- task-dependent changes, plasticity, 11
- task factors *see* intra-individual variability
- task practice, CIMT, 407, 408
- task selection, CIMT, 408
- taste aversion conditioning, plasticity, 16
- telephone therapy, auditory comprehension treatments, 442
- tele-rehabilitation *see* psychosocial factors

- temporal frontal regions, aging-related changes, 155
- temporal information
  - EEG, 183
  - magnetoencephalography, 183
- Test of Everyday Attention (TEA)
  - attention assessment, 98
  - cognitive activity assessment, 97
- testosterone, 68
  - neurogenesis, 352
- test-retest reliability, definition, 92
- thalamus, frontal subcortical circuits, 206
- three-dimensional magnetic resonance imaging *see*
  - magnetic resonance imaging (MRI)
- “three vectors of consciousness”, anosognosia treatment, 226
- thrombosis, nitric oxide, 261
- tianeptine, 65
- time-dependency, plasticity *see* plasticity
- time for performance, cognitive function enhancement, 311
- time of day, age-related memory rehabilitation, 550
- Time Pressure Management (TPM), 513
- time scales, intra-individual variability, 43
- time-series, neuroelectric recordings, 186, 187
- time since injury, frontal lobe function rehabilitation, 478
- Tirilazad, 305
- tissue plasminogen activator (tPA), stroke, 377, 387
- Token Test, 441
- tolerability, randomized clinical trials, 81
- tools, cognitive neurorehabilitation, 567
- topographical changes
  - event-related fields, 193
  - event-related potentials, 193
  - neuroelectric recordings, 183
  - neuromagnetic recordings, 183
- Tower of London task, 492
- Trail Making Test
  - attention, 508, 512
  - executive/cognitive function rehabilitation, 472
- trainer-trainee interaction patterns, psychosocial factors, 243
- training
  - auditory comprehension treatments, 441
  - mismatch negativity, 190
  - neurogenesis, 353
  - retrieval processes *see* memory rehabilitation, elderly
  - somatosensory evoked responses, 192
  - visual evoked responses, 191
- transcranial magnetic stimulation (TMS), 167
  - CIMT, 404, 405
- “transfer packages”, CIMT, 410
- translational linkages, cognitive neurorehabilitation, 567
- translational research
  - definition, 80
  - rehabilitation research, 80
- translation stage, Rothi’s multistage model, 4
- transplantation, neural stem cells *see* neural stem cell therapy
- trauma
  - compensation, 25
  - neurogenesis, 352
  - plasticity in brain injury, 12
- traumatic brain injury (TBI), 469
  - case study, variability, 52
- children *see below*
- classification, 303
- cognitive sequelae, 322, 507
- compensation, 30
- DA, 307
- epinephrine, 307
- incidence, 469, 507
- intra-individual variability *see* intra-individual variability
- NE, 307
- neuropathology, 321
- neurotransmitters, 321, 322
- pathogenesis
  - focal parenchymal injury, 469
  - frontal lobe disorder, 468
- Patient Competency Rating Scale, 227
- pharmacological therapy, 295, 321–333
- primary prevention, 302
- rehabilitation therapy
  - case study, 54
  - effectiveness evidence, 107
  - intra-individual variability, 53
  - psychosocial factors, 233
  - treatment effectiveness evidence, 107
- reviews (of cognitive rehabilitation), 107
- secondary effects, 507
- studies
  - eligibility criteria, 112
  - error awareness/self-monitoring, 476
  - randomisation, 111
  - self-efficacy, 237
- treatment
  - behavioral therapy, 399
  - community-based interventions, 241
  - memory *see* memory rehabilitation, post-injury
  - pharmacological therapy *see above*
  - rehabilitation therapy *see above*
  - stem cell therapy, 307
  - tele-rehabilitation, 242

- traumatic brain injury (TBI), children
  - ADHD vs. *see* attention deficit hyperactivity disorder (ADHD)
  - behavioral self-regulation, 494
  - decision making/motivation, 493
  - everyday activities, 494–495
  - executive functioning, 487, 488
  - inhibition, 491
  - neural substrate, 489
  - neurocircuitry, 497
  - planning, 492
  - recovery/treatment, 497–499
- traumatic spinal cord injury (TSCI),
  - anosognosia, 222
- trazodone, clinical trials, 342
- treatment allocation concealment, randomization, 111
- treatment descriptions, methodological quality
  - evaluation *see* methodological quality evaluation
- treatment efficacy, randomized clinical trials, 82
- treatment outcome evaluation, outcome measures, 87
- treatment periods, blind multiple cross-over trials, 329
- tricyclic antidepressants, depression, 210
- tumor necrosis factor-alpha, type-2 diabetes mellitus, 276
- tumors, 468–469
- two-dimensional magnetic resonance imaging, 135
- type 1 allostatic load, allostasis, 62
- type 2 allostatic load, allostasis, 62
- type-2 diabetes mellitus
  - acute diet, 281
  - chronic diet, 273
  - inflammation, 276–277
  - insulin signaling, 273, 274
  - oxidative stress, 276–277
  - tumor necrosis factor-alpha, 276
- unilateral brain injury, neglect syndrome, 449
- unilateral spatial neglect
  - anosognosia comorbidity, 221
  - Rothi's revision of the Robey model, 85
  - TBI effects, 508
- use-dependent cortical reorganization *see* constraint-induced movement therapy (CIMT)
- validation, psychosocial factors, 234
- validity, outcome measures, 92, 100
- valproate
  - bipolar affective disorder, 211
  - TBI, 324
- vanishing cues, age-related memory
  - rehabilitation, 552
- variability, 39–61
- variance, 46
- vascular cognitive impairment (VCI), 361
- vascular cognitive impairment no dementia (vCIND),
  - physical activity vs., 266
- vascular dementia (VaD)
  - cerebral hypoperfusion, 263
  - definition, 251
  - executive dysfunction, 250, 264
  - exercise intervention studies, 256
  - gait disorders, 265, 266
  - homocysteine, 262
  - incidence, 337
  - intra-individual variability, 48
  - nitric oxide metabolism, 262
  - pathology, 337
  - pharmacological therapy, 343
  - vascular disease, 260–261
- vascular disease, 250
  - Alzheimer's disease *see* Alzheimer's disease
  - basal forebrain, 260
  - cerebral hypoperfusion, 260–261
  - effects of, 266
  - exercise, 251, 259–265
  - frontotemporal dementia, 261
  - homocysteine, 261
  - physical activity decrease, 266
  - vascular dementia *see* vascular dementia (VaD)
  - see also specific diseases/disorders*
- vascular endothelial growth factor (VEGF)
  - exercise/physical activity, 420
  - neurogenesis, 422
  - neural stem cell therapy, 382, 383
  - neurogenesis, 379, 422
- vascular injury, prevention of, 125
- vasculitis, cerebral amyloid angiopathy, 365
- vegetative state, TBI, 321
- ventral hippocampal lesions, animal models of plasticity, 17
- ventral prefrontal cortex (VPFC), 465, 466
- ventral striatum, 488
- ventrolateral prefrontal cortex, 488
- ventromedial frontal cortex, 493
- verbal apraxia, 136
- verbal fluency, 439
  - card games, 441
  - definition, 440
  - discourse level training, 440

- verbal fluency (cont.)
  - functional conversation skills, 440
  - lesion-behavior analysis, 141
  - Melodic Intonational Therapy, 440, 441
  - PACE, 440
  - Response Elaboration Training, 440, 441
  - self-monitoring treatment, 440
  - TAP program, 440
  - see also entries under language*
- verbal memory, insulin signaling, 274
- verbal reinstatement strategy, 476
- verb retrieval treatment, 439
- video feedback, neglect syndrome rehabilitation, 452
- viral vectors, neurogenesis, 354
- Virchow–Robin spaces, MRI, 127, 143
- virtual reality, memory impairment rehabilitation, 531–532
- Visual Analog Mood Scales, 96
- visual area, 7
- visual evoked responses, 191–192
- visual imagery
  - age-related memory rehabilitation *see* memory rehabilitation, elderly
  - memory impairment rehabilitation, 527
  - mnemonics, 528
- visual neglect assessment, 97–98
- visual processing, Rothi’s revision of the Robey model, 85
- visual scanning, neglect syndrome rehabilitation, 452
- visual stimuli processing, event-related potentials, 194
- visual system, translational research, 84
- visuomotor feedback, neglect syndrome rehabilitation, 452
- visuoverbal measures, prism adaptation, 456
- vitamin C, 283
- vitamin E, 283
  - clinical trials, 340
- volumetric MRI, TBI, 497
- voluntary exercise
  - behavioral animal studies, 419
  - neurogenesis, 421
- voluntary running behavior tests, 356
- Voxel-based Lesion Symptom mapping, 140, 141
- WAIS-III
  - Patient Competency Rating Scale, 227
  - scatter, 50
- WAIS-R, scatter, 50
- walking/talking, Alzheimer’s disease therapy, 252, 256
- war-related injuries, aphasia, 436
- Weschler intelligence scales, scatter, 46
- wheel running, behavioral animal studies, 418
- white boards, proximal memory aids, 524
- white matter
  - cerebral hypoperfusion *see* cerebral hypoperfusion
  - memory, aging effects, 543, 544
- Wisconsin Card Sorting Test (WCST)
  - ADHD, 491
  - attention rehabilitation, 512
  - in children, post TBI, 491
- Wolf Motor Function Test (WMFT), 406
- Women’s Health Initiative (WHI), 67
- word level treatments *see* language production therapy
- workbook interventions, psychosocial factors, 243
- working alliances, post-TBI anosognosia therapy studies, 224
- working memory, 299
  - A1A agonist effects, 301
  - aging effects, 150, 151, 542
  - catecholaminergic system, 299
  - children, 490
  - cholinergic system, 299
  - definition, 490
  - neurotransmitters, 299
  - pharmacologic therapy, 313
  - rehabilitation, 472
- World Health Organization (WHO), rehabilitation research
  - phase models, 81
- Zucker rat model, obesity, 69